Latest COVID-19 Shot May Cut Severe Outcomes in Veterans

Article Type
Changed

TOPLINE: 

Among US veterans, same-day receipt of both the 2024-2025 COVID19 vaccine and the influenza vaccine was associated with lower risks for emergency department visits, hospitalizations, and deaths compared with receipt of the influenza vaccine alone.

METHODOLOGY:

  • Researchers conducted an observational study to assess the effectiveness of the 2024-2025 COVID-19 vaccine by comparing veterans who received both the COVID-19 and influenza vaccines on the same day with those who received only the influenza vaccine between September 3 and December 31, 2024.
  • Data on participants (mean age, approximately 71.5 years; approximately 92% men) were sourced from electronic health records of the Department of Veterans Affairs and included 164,132 veterans who received both vaccines vs 131,839 who received only the seasonal influenza vaccine, with a follow-up duration of 180 days.
  • The vaccines used were mainly the 2024-2025 mRNA COVID19 vaccines: Moderna mRNA1273, Pfizer BNT162b2, and the highdose trivalent 2024-2025 seasonal influenza vaccine.
  • Primary outcomes were COVID-19-associated emergency department visits, hospitalizations, and deaths.

TAKEAWAY:

  • Receipt of both the COVID-19 and influenza vaccines was associated with a lower risk for COVID-19-associated emergency department visits compared with receipt of the influenza vaccine alone, resulting in a vaccine effectiveness of 29.3% and a risk difference of 18.3 per 10,000 persons (95% CI, 10.8-27.6).
  • Similarly, COVID-19 vaccine effectiveness was 39.2% (95% CI, 21.6-54.5) against COVID-19-associated hospitalizations, with a risk difference of 7.5 per 10,000 persons (95% CI, 3.4-13.0).
  • For COVID-19-associated deaths, vaccine effectiveness was 64% (95% CI, 23.0-85.8), with a risk difference of 2.2 per 10,000 persons (95% CI, 0.5-6.9).
  • Benefits were consistent across age groups (< 65, 65-75, and > 75 years) and among people with various comorbidities, including cardiovascular disease and immunocompromised status.

IN PRACTICE:

“The evidence may help inform ongoing discussions about the value of COVID-19 vaccines in the current epidemiologic landscape,” the authors wrote.

SOURCE:

The study was led by Miao Cai, PhD , Research and Development Service, Veterans Affairs St. Louis Health Care System, and the Veterans Research and Education Foundation of St. Louis, Missouri. It was published online in The New England Journal of Medicine .

LIMITATIONS:

The demographic composition of the cohort — predominantly older, White, male veterans — may limit the generalizability of the study. Although numerous covariates were adjusted for, residual confounding could not be fully ruled out. Safety and variantspecific effectiveness were not assessed.

DISCLOSURES:

The study was supported by a grant from the Department of Veterans Affairs. Two authors disclosed consulting for Pfizer.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.

Publications
Topics
Sections

TOPLINE: 

Among US veterans, same-day receipt of both the 2024-2025 COVID19 vaccine and the influenza vaccine was associated with lower risks for emergency department visits, hospitalizations, and deaths compared with receipt of the influenza vaccine alone.

METHODOLOGY:

  • Researchers conducted an observational study to assess the effectiveness of the 2024-2025 COVID-19 vaccine by comparing veterans who received both the COVID-19 and influenza vaccines on the same day with those who received only the influenza vaccine between September 3 and December 31, 2024.
  • Data on participants (mean age, approximately 71.5 years; approximately 92% men) were sourced from electronic health records of the Department of Veterans Affairs and included 164,132 veterans who received both vaccines vs 131,839 who received only the seasonal influenza vaccine, with a follow-up duration of 180 days.
  • The vaccines used were mainly the 2024-2025 mRNA COVID19 vaccines: Moderna mRNA1273, Pfizer BNT162b2, and the highdose trivalent 2024-2025 seasonal influenza vaccine.
  • Primary outcomes were COVID-19-associated emergency department visits, hospitalizations, and deaths.

TAKEAWAY:

  • Receipt of both the COVID-19 and influenza vaccines was associated with a lower risk for COVID-19-associated emergency department visits compared with receipt of the influenza vaccine alone, resulting in a vaccine effectiveness of 29.3% and a risk difference of 18.3 per 10,000 persons (95% CI, 10.8-27.6).
  • Similarly, COVID-19 vaccine effectiveness was 39.2% (95% CI, 21.6-54.5) against COVID-19-associated hospitalizations, with a risk difference of 7.5 per 10,000 persons (95% CI, 3.4-13.0).
  • For COVID-19-associated deaths, vaccine effectiveness was 64% (95% CI, 23.0-85.8), with a risk difference of 2.2 per 10,000 persons (95% CI, 0.5-6.9).
  • Benefits were consistent across age groups (< 65, 65-75, and > 75 years) and among people with various comorbidities, including cardiovascular disease and immunocompromised status.

IN PRACTICE:

“The evidence may help inform ongoing discussions about the value of COVID-19 vaccines in the current epidemiologic landscape,” the authors wrote.

SOURCE:

The study was led by Miao Cai, PhD , Research and Development Service, Veterans Affairs St. Louis Health Care System, and the Veterans Research and Education Foundation of St. Louis, Missouri. It was published online in The New England Journal of Medicine .

LIMITATIONS:

The demographic composition of the cohort — predominantly older, White, male veterans — may limit the generalizability of the study. Although numerous covariates were adjusted for, residual confounding could not be fully ruled out. Safety and variantspecific effectiveness were not assessed.

DISCLOSURES:

The study was supported by a grant from the Department of Veterans Affairs. Two authors disclosed consulting for Pfizer.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.

TOPLINE: 

Among US veterans, same-day receipt of both the 2024-2025 COVID19 vaccine and the influenza vaccine was associated with lower risks for emergency department visits, hospitalizations, and deaths compared with receipt of the influenza vaccine alone.

METHODOLOGY:

  • Researchers conducted an observational study to assess the effectiveness of the 2024-2025 COVID-19 vaccine by comparing veterans who received both the COVID-19 and influenza vaccines on the same day with those who received only the influenza vaccine between September 3 and December 31, 2024.
  • Data on participants (mean age, approximately 71.5 years; approximately 92% men) were sourced from electronic health records of the Department of Veterans Affairs and included 164,132 veterans who received both vaccines vs 131,839 who received only the seasonal influenza vaccine, with a follow-up duration of 180 days.
  • The vaccines used were mainly the 2024-2025 mRNA COVID19 vaccines: Moderna mRNA1273, Pfizer BNT162b2, and the highdose trivalent 2024-2025 seasonal influenza vaccine.
  • Primary outcomes were COVID-19-associated emergency department visits, hospitalizations, and deaths.

TAKEAWAY:

  • Receipt of both the COVID-19 and influenza vaccines was associated with a lower risk for COVID-19-associated emergency department visits compared with receipt of the influenza vaccine alone, resulting in a vaccine effectiveness of 29.3% and a risk difference of 18.3 per 10,000 persons (95% CI, 10.8-27.6).
  • Similarly, COVID-19 vaccine effectiveness was 39.2% (95% CI, 21.6-54.5) against COVID-19-associated hospitalizations, with a risk difference of 7.5 per 10,000 persons (95% CI, 3.4-13.0).
  • For COVID-19-associated deaths, vaccine effectiveness was 64% (95% CI, 23.0-85.8), with a risk difference of 2.2 per 10,000 persons (95% CI, 0.5-6.9).
  • Benefits were consistent across age groups (< 65, 65-75, and > 75 years) and among people with various comorbidities, including cardiovascular disease and immunocompromised status.

IN PRACTICE:

“The evidence may help inform ongoing discussions about the value of COVID-19 vaccines in the current epidemiologic landscape,” the authors wrote.

SOURCE:

The study was led by Miao Cai, PhD , Research and Development Service, Veterans Affairs St. Louis Health Care System, and the Veterans Research and Education Foundation of St. Louis, Missouri. It was published online in The New England Journal of Medicine .

LIMITATIONS:

The demographic composition of the cohort — predominantly older, White, male veterans — may limit the generalizability of the study. Although numerous covariates were adjusted for, residual confounding could not be fully ruled out. Safety and variantspecific effectiveness were not assessed.

DISCLOSURES:

The study was supported by a grant from the Department of Veterans Affairs. Two authors disclosed consulting for Pfizer.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Targeted Osteoporosis Program May Benefit At-Risk Older Men

Article Type
Changed

Efforts to identify older men at risk for osteoporosis and treat those who are eligible received a boost from results reported from a Veterans Affairs (VA) study that showed a significant increase in screening, treatment, and medication adherence.

The cluster randomized trial used a centralized nurse-led intervention to assess men for traditional osteoporosis risk factors, offer bone density testing, and recommend treatment for eligible men. Over 2 years, the intervention group had a higher average femoral neck bone density than patients who underwent usual care.

“We designed this study to see if a risk factor-based approach, which is what most of the guidelines use, made sense and was feasible — that men would be accepting of screening and [the approach] would yield a similar proportion of people who need osteoporosis treatment as screening in women, which is widely recommended and implemented. And sure enough, we found that about 85% of the men in the VA primary care practices in our target age range of between 65 and 85 actually met criteria for screening, and over half of them had low bone mass. They were very accepting of screening, very accepting of treatment, and had excellent compliance rates. So, our study, we believe, supports the idea of identifying men with at least one risk factor for fracture and offering them osteoporosis screening starting at age 65, similar to what we do for women,” Cathleen S. Colón-Emeric, MD, MHS, said in an interview. She is the lead author of the study, a physician in the Durham VA Health Care System, and professor of medicine at Duke University School of Medicine, Durham, North Carolina.

“We were able to see a positive effect on bone density in the bone health group, compared with the usual care group, which suggests that if we followed these folks longer and had enough of them, we would be able to show a fracture reduction benefit,” Colón-Emeric said.

There have been few randomized trials of screening interventions in men, leading to inconsistencies in guidelines, according to the authors of the new study, published online in JAMA Internal Medicine . Both the US Preventive Services Task Force and the Veterans Health Administration National Center for Health Promotion and Disease Prevention consider there to be insufficient evidence to recommend for or against screening in men who have not experienced a fracture. Some professional societies recommend such screening, but there are inconsistencies in the recommended criteria, such as age range or risk factors.

Beyond the age of 50 years, one in five men will experience an osteoporosis-related fracture at some point in their life, according to a 2009 study. Treatment is inexpensive and effective in both men and women, and economic models suggest that screening using dual-energy x-ray absorptiometry (DXA) would be cost-effective. Still, screening is rare among men, with fewer than 10% of men getting screened before having an osteoporosis-related fracture.

“It’s important to screen men at risk for osteoporosis due to the dramatically increased mortality men suffer after a fragility fracture compared with women. Within 1 year of a hip fracture, mortality is as high as 36%. Studies have also shown that osteoporosis in men is undertreated, with only 10%-50% being prescribed antifracture treatment within 1 year of a hip fracture. Most individuals do not regain their prior level of function after a hip fracture,” said Joe C. Huang, MD, who was asked for comment. He is a clinical assistant professor of gerontology and geriatric medicine at Harborview Medical Center Senior Care Clinic and Healthy Bones Clinic in Seattle.

 

Details of the Intervention

The bone health service (BHS) intervention employed an electronic health record case-finding tool and a nurse care manager who undertook screening and treatment monitoring. They identified potential risk factors that included hyperthyroidismhyperparathyroidismrheumatoid arthritisalcohol dependence, chronic lung disease, chronic liver disease, stroke, parkinsonism, prostate cancer, smoking, diabetes, pernicious anemia, gastrectomy, or high-risk medication use in at least 3 months of the prior 2 years. These medications included traditional antiepileptics, glucocorticoids, and androgen deprivation therapy.

The BHS nurse invited eligible men to be screened using an initial letter, followed by up to three phone calls. After DXA screening, the nurse scheduled an electronic consult with an osteoporosis expert, and patients with a T-score between -1 and -2.4 and an elevated 10-year fracture risk as measured by the Fracture Risk Assessment Tool were recommended for osteoporosis medication, vitamin D, and dietary or supplemental calcium. Following the prescription, the nurse provided patient education over the phone and mailed out written instructions. The nurse also made phone calls at 1 month, 6 months, and 12 months to encourage adherence and address common treatment barriers such as forgetting to take medication or dealing with gastrointestinal effects. The researchers recruited 38 primary care physicians from two VA health systems. The study included 3112 male veterans between the ages of 65 and 85 years (40.4% Black and 56% White). Nearly all participants (85.5%) had at least one indication for screening according to VA undersecretary guidelines, and almost a third (32.1%) had been prescribed androgen deprivation therapy, traditional antiepileptic drugs, or glucocorticoids.

Over a mean follow-up of 1.5 years, there was a much higher screening rate in the BHS group (49.2% vs 2.3%; P < .001), with a similar overall yield of DXA results recommending osteoporosis treatment (22.4% vs 27.2%). In the BHS group, 84.4% of patients who had treatment recommended followed through with treatment initiation. The mean persistence over follow-up was 657 days (SD, 366 days), and adherence was high with a mean proportion of days covered of 91.7%.

It was not possible to statistically compare adherence with the usual-care group because there were too few screened patients found to be eligible for treatment in that group, but the historic mean proportion of days covered at the two participating facilities was 52%. 

After 2 years, the mean femoral neck T-score tested randomly in a subset of patients was better in the BHS arm, although it did not meet statistical significance according to the Bonferroni corrected criterion of P < .025 (-0.55 vs -0.70; P = .04). Fracture rates were similar between the two groups (1.8% vs 2.0%; P = .69). 

 

Can the Findings Be Translated Across Clinics?

It remains to be seen how well the model could translate to other healthcare settings, according to Kenny Lin, MD, MPH, who was asked for comment on the study. “Outside of the VA health system and perhaps integrated HMOs [health maintenance organizations] such as Kaiser, Geisinger, etc., it seems unlikely that most primary care docs will have access to a centralized bone health service. Who’s going to pay for it? It leaves unanswered the question of whether it’s more efficient to address [osteoporosis] screening on a practice or population level. I suspect the latter is probably superior, but this study doesn’t provide any empiric evidence that this is so,” said Lin, associate director of the Penn Medicine Lancaster General Hospital’s Family Medicine Residency Program, Lancaster, Pennsylvania. The findings could help sway recommendations to screen men for osteoporosis, according to Susan Ott, MD, who was also asked for comment. Guideline committees “have been trying to be very scientific [about it]. I think they overdo it because they only look at one or two kinds of studies, and there are more kinds of science than just a randomized clinical trial. But they’re kind of stuck on that. The fact that this study was a randomized trial maybe they will finally change their recommendation, because there really shouldn’t be any difference in screening for men and for women. The men are actually discriminated against,” said Ott, emeritus professor of medicine at the University of Washington, Seattle.

In fact, she noted that the risks for men are similar to those for women, except that men tend to develop issues 5-10 years later in life. To screen and treat men, healthcare systems can “do the same thing they do with women. Just change the age range,” Ott said.

Lin sounded a different note, suggesting that the focus should remain on improvement of screening and treatment adherence in women. “We know that up to two thirds of women discontinue osteoporosis drugs within a year, and if we can’t figure out how to improve abysmal adherence in women, it’s unlikely we will persuade enough men to take these drugs to make a difference,” he said.

The study was funded by a grant from the VA Health Systems Research. Colón-Emeric, Lin, Ott, and Huang reported having no relevant financial disclosures.

A version of this article first appeared on Medscape.com.

Publications
Topics
Sections

Efforts to identify older men at risk for osteoporosis and treat those who are eligible received a boost from results reported from a Veterans Affairs (VA) study that showed a significant increase in screening, treatment, and medication adherence.

The cluster randomized trial used a centralized nurse-led intervention to assess men for traditional osteoporosis risk factors, offer bone density testing, and recommend treatment for eligible men. Over 2 years, the intervention group had a higher average femoral neck bone density than patients who underwent usual care.

“We designed this study to see if a risk factor-based approach, which is what most of the guidelines use, made sense and was feasible — that men would be accepting of screening and [the approach] would yield a similar proportion of people who need osteoporosis treatment as screening in women, which is widely recommended and implemented. And sure enough, we found that about 85% of the men in the VA primary care practices in our target age range of between 65 and 85 actually met criteria for screening, and over half of them had low bone mass. They were very accepting of screening, very accepting of treatment, and had excellent compliance rates. So, our study, we believe, supports the idea of identifying men with at least one risk factor for fracture and offering them osteoporosis screening starting at age 65, similar to what we do for women,” Cathleen S. Colón-Emeric, MD, MHS, said in an interview. She is the lead author of the study, a physician in the Durham VA Health Care System, and professor of medicine at Duke University School of Medicine, Durham, North Carolina.

“We were able to see a positive effect on bone density in the bone health group, compared with the usual care group, which suggests that if we followed these folks longer and had enough of them, we would be able to show a fracture reduction benefit,” Colón-Emeric said.

There have been few randomized trials of screening interventions in men, leading to inconsistencies in guidelines, according to the authors of the new study, published online in JAMA Internal Medicine . Both the US Preventive Services Task Force and the Veterans Health Administration National Center for Health Promotion and Disease Prevention consider there to be insufficient evidence to recommend for or against screening in men who have not experienced a fracture. Some professional societies recommend such screening, but there are inconsistencies in the recommended criteria, such as age range or risk factors.

Beyond the age of 50 years, one in five men will experience an osteoporosis-related fracture at some point in their life, according to a 2009 study. Treatment is inexpensive and effective in both men and women, and economic models suggest that screening using dual-energy x-ray absorptiometry (DXA) would be cost-effective. Still, screening is rare among men, with fewer than 10% of men getting screened before having an osteoporosis-related fracture.

“It’s important to screen men at risk for osteoporosis due to the dramatically increased mortality men suffer after a fragility fracture compared with women. Within 1 year of a hip fracture, mortality is as high as 36%. Studies have also shown that osteoporosis in men is undertreated, with only 10%-50% being prescribed antifracture treatment within 1 year of a hip fracture. Most individuals do not regain their prior level of function after a hip fracture,” said Joe C. Huang, MD, who was asked for comment. He is a clinical assistant professor of gerontology and geriatric medicine at Harborview Medical Center Senior Care Clinic and Healthy Bones Clinic in Seattle.

 

Details of the Intervention

The bone health service (BHS) intervention employed an electronic health record case-finding tool and a nurse care manager who undertook screening and treatment monitoring. They identified potential risk factors that included hyperthyroidismhyperparathyroidismrheumatoid arthritisalcohol dependence, chronic lung disease, chronic liver disease, stroke, parkinsonism, prostate cancer, smoking, diabetes, pernicious anemia, gastrectomy, or high-risk medication use in at least 3 months of the prior 2 years. These medications included traditional antiepileptics, glucocorticoids, and androgen deprivation therapy.

The BHS nurse invited eligible men to be screened using an initial letter, followed by up to three phone calls. After DXA screening, the nurse scheduled an electronic consult with an osteoporosis expert, and patients with a T-score between -1 and -2.4 and an elevated 10-year fracture risk as measured by the Fracture Risk Assessment Tool were recommended for osteoporosis medication, vitamin D, and dietary or supplemental calcium. Following the prescription, the nurse provided patient education over the phone and mailed out written instructions. The nurse also made phone calls at 1 month, 6 months, and 12 months to encourage adherence and address common treatment barriers such as forgetting to take medication or dealing with gastrointestinal effects. The researchers recruited 38 primary care physicians from two VA health systems. The study included 3112 male veterans between the ages of 65 and 85 years (40.4% Black and 56% White). Nearly all participants (85.5%) had at least one indication for screening according to VA undersecretary guidelines, and almost a third (32.1%) had been prescribed androgen deprivation therapy, traditional antiepileptic drugs, or glucocorticoids.

Over a mean follow-up of 1.5 years, there was a much higher screening rate in the BHS group (49.2% vs 2.3%; P < .001), with a similar overall yield of DXA results recommending osteoporosis treatment (22.4% vs 27.2%). In the BHS group, 84.4% of patients who had treatment recommended followed through with treatment initiation. The mean persistence over follow-up was 657 days (SD, 366 days), and adherence was high with a mean proportion of days covered of 91.7%.

It was not possible to statistically compare adherence with the usual-care group because there were too few screened patients found to be eligible for treatment in that group, but the historic mean proportion of days covered at the two participating facilities was 52%. 

After 2 years, the mean femoral neck T-score tested randomly in a subset of patients was better in the BHS arm, although it did not meet statistical significance according to the Bonferroni corrected criterion of P < .025 (-0.55 vs -0.70; P = .04). Fracture rates were similar between the two groups (1.8% vs 2.0%; P = .69). 

 

Can the Findings Be Translated Across Clinics?

It remains to be seen how well the model could translate to other healthcare settings, according to Kenny Lin, MD, MPH, who was asked for comment on the study. “Outside of the VA health system and perhaps integrated HMOs [health maintenance organizations] such as Kaiser, Geisinger, etc., it seems unlikely that most primary care docs will have access to a centralized bone health service. Who’s going to pay for it? It leaves unanswered the question of whether it’s more efficient to address [osteoporosis] screening on a practice or population level. I suspect the latter is probably superior, but this study doesn’t provide any empiric evidence that this is so,” said Lin, associate director of the Penn Medicine Lancaster General Hospital’s Family Medicine Residency Program, Lancaster, Pennsylvania. The findings could help sway recommendations to screen men for osteoporosis, according to Susan Ott, MD, who was also asked for comment. Guideline committees “have been trying to be very scientific [about it]. I think they overdo it because they only look at one or two kinds of studies, and there are more kinds of science than just a randomized clinical trial. But they’re kind of stuck on that. The fact that this study was a randomized trial maybe they will finally change their recommendation, because there really shouldn’t be any difference in screening for men and for women. The men are actually discriminated against,” said Ott, emeritus professor of medicine at the University of Washington, Seattle.

In fact, she noted that the risks for men are similar to those for women, except that men tend to develop issues 5-10 years later in life. To screen and treat men, healthcare systems can “do the same thing they do with women. Just change the age range,” Ott said.

Lin sounded a different note, suggesting that the focus should remain on improvement of screening and treatment adherence in women. “We know that up to two thirds of women discontinue osteoporosis drugs within a year, and if we can’t figure out how to improve abysmal adherence in women, it’s unlikely we will persuade enough men to take these drugs to make a difference,” he said.

The study was funded by a grant from the VA Health Systems Research. Colón-Emeric, Lin, Ott, and Huang reported having no relevant financial disclosures.

A version of this article first appeared on Medscape.com.

Efforts to identify older men at risk for osteoporosis and treat those who are eligible received a boost from results reported from a Veterans Affairs (VA) study that showed a significant increase in screening, treatment, and medication adherence.

The cluster randomized trial used a centralized nurse-led intervention to assess men for traditional osteoporosis risk factors, offer bone density testing, and recommend treatment for eligible men. Over 2 years, the intervention group had a higher average femoral neck bone density than patients who underwent usual care.

“We designed this study to see if a risk factor-based approach, which is what most of the guidelines use, made sense and was feasible — that men would be accepting of screening and [the approach] would yield a similar proportion of people who need osteoporosis treatment as screening in women, which is widely recommended and implemented. And sure enough, we found that about 85% of the men in the VA primary care practices in our target age range of between 65 and 85 actually met criteria for screening, and over half of them had low bone mass. They were very accepting of screening, very accepting of treatment, and had excellent compliance rates. So, our study, we believe, supports the idea of identifying men with at least one risk factor for fracture and offering them osteoporosis screening starting at age 65, similar to what we do for women,” Cathleen S. Colón-Emeric, MD, MHS, said in an interview. She is the lead author of the study, a physician in the Durham VA Health Care System, and professor of medicine at Duke University School of Medicine, Durham, North Carolina.

“We were able to see a positive effect on bone density in the bone health group, compared with the usual care group, which suggests that if we followed these folks longer and had enough of them, we would be able to show a fracture reduction benefit,” Colón-Emeric said.

There have been few randomized trials of screening interventions in men, leading to inconsistencies in guidelines, according to the authors of the new study, published online in JAMA Internal Medicine . Both the US Preventive Services Task Force and the Veterans Health Administration National Center for Health Promotion and Disease Prevention consider there to be insufficient evidence to recommend for or against screening in men who have not experienced a fracture. Some professional societies recommend such screening, but there are inconsistencies in the recommended criteria, such as age range or risk factors.

Beyond the age of 50 years, one in five men will experience an osteoporosis-related fracture at some point in their life, according to a 2009 study. Treatment is inexpensive and effective in both men and women, and economic models suggest that screening using dual-energy x-ray absorptiometry (DXA) would be cost-effective. Still, screening is rare among men, with fewer than 10% of men getting screened before having an osteoporosis-related fracture.

“It’s important to screen men at risk for osteoporosis due to the dramatically increased mortality men suffer after a fragility fracture compared with women. Within 1 year of a hip fracture, mortality is as high as 36%. Studies have also shown that osteoporosis in men is undertreated, with only 10%-50% being prescribed antifracture treatment within 1 year of a hip fracture. Most individuals do not regain their prior level of function after a hip fracture,” said Joe C. Huang, MD, who was asked for comment. He is a clinical assistant professor of gerontology and geriatric medicine at Harborview Medical Center Senior Care Clinic and Healthy Bones Clinic in Seattle.

 

Details of the Intervention

The bone health service (BHS) intervention employed an electronic health record case-finding tool and a nurse care manager who undertook screening and treatment monitoring. They identified potential risk factors that included hyperthyroidismhyperparathyroidismrheumatoid arthritisalcohol dependence, chronic lung disease, chronic liver disease, stroke, parkinsonism, prostate cancer, smoking, diabetes, pernicious anemia, gastrectomy, or high-risk medication use in at least 3 months of the prior 2 years. These medications included traditional antiepileptics, glucocorticoids, and androgen deprivation therapy.

The BHS nurse invited eligible men to be screened using an initial letter, followed by up to three phone calls. After DXA screening, the nurse scheduled an electronic consult with an osteoporosis expert, and patients with a T-score between -1 and -2.4 and an elevated 10-year fracture risk as measured by the Fracture Risk Assessment Tool were recommended for osteoporosis medication, vitamin D, and dietary or supplemental calcium. Following the prescription, the nurse provided patient education over the phone and mailed out written instructions. The nurse also made phone calls at 1 month, 6 months, and 12 months to encourage adherence and address common treatment barriers such as forgetting to take medication or dealing with gastrointestinal effects. The researchers recruited 38 primary care physicians from two VA health systems. The study included 3112 male veterans between the ages of 65 and 85 years (40.4% Black and 56% White). Nearly all participants (85.5%) had at least one indication for screening according to VA undersecretary guidelines, and almost a third (32.1%) had been prescribed androgen deprivation therapy, traditional antiepileptic drugs, or glucocorticoids.

Over a mean follow-up of 1.5 years, there was a much higher screening rate in the BHS group (49.2% vs 2.3%; P < .001), with a similar overall yield of DXA results recommending osteoporosis treatment (22.4% vs 27.2%). In the BHS group, 84.4% of patients who had treatment recommended followed through with treatment initiation. The mean persistence over follow-up was 657 days (SD, 366 days), and adherence was high with a mean proportion of days covered of 91.7%.

It was not possible to statistically compare adherence with the usual-care group because there were too few screened patients found to be eligible for treatment in that group, but the historic mean proportion of days covered at the two participating facilities was 52%. 

After 2 years, the mean femoral neck T-score tested randomly in a subset of patients was better in the BHS arm, although it did not meet statistical significance according to the Bonferroni corrected criterion of P < .025 (-0.55 vs -0.70; P = .04). Fracture rates were similar between the two groups (1.8% vs 2.0%; P = .69). 

 

Can the Findings Be Translated Across Clinics?

It remains to be seen how well the model could translate to other healthcare settings, according to Kenny Lin, MD, MPH, who was asked for comment on the study. “Outside of the VA health system and perhaps integrated HMOs [health maintenance organizations] such as Kaiser, Geisinger, etc., it seems unlikely that most primary care docs will have access to a centralized bone health service. Who’s going to pay for it? It leaves unanswered the question of whether it’s more efficient to address [osteoporosis] screening on a practice or population level. I suspect the latter is probably superior, but this study doesn’t provide any empiric evidence that this is so,” said Lin, associate director of the Penn Medicine Lancaster General Hospital’s Family Medicine Residency Program, Lancaster, Pennsylvania. The findings could help sway recommendations to screen men for osteoporosis, according to Susan Ott, MD, who was also asked for comment. Guideline committees “have been trying to be very scientific [about it]. I think they overdo it because they only look at one or two kinds of studies, and there are more kinds of science than just a randomized clinical trial. But they’re kind of stuck on that. The fact that this study was a randomized trial maybe they will finally change their recommendation, because there really shouldn’t be any difference in screening for men and for women. The men are actually discriminated against,” said Ott, emeritus professor of medicine at the University of Washington, Seattle.

In fact, she noted that the risks for men are similar to those for women, except that men tend to develop issues 5-10 years later in life. To screen and treat men, healthcare systems can “do the same thing they do with women. Just change the age range,” Ott said.

Lin sounded a different note, suggesting that the focus should remain on improvement of screening and treatment adherence in women. “We know that up to two thirds of women discontinue osteoporosis drugs within a year, and if we can’t figure out how to improve abysmal adherence in women, it’s unlikely we will persuade enough men to take these drugs to make a difference,” he said.

The study was funded by a grant from the VA Health Systems Research. Colón-Emeric, Lin, Ott, and Huang reported having no relevant financial disclosures.

A version of this article first appeared on Medscape.com.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

U.S. Health Chief Kennedy Targets Vaccine Injury Compensation Program

Article Type
Changed

WASHINGTON (Reuters) - U.S. Health Secretary Robert F. Kennedy Jr. said on July 28 that he will work to “fix” the program that compensates victims of vaccine injuries, the National Vaccine Injury Compensation Program.

Kennedy, a long-time vaccine skeptic and former vaccine injury plaintiff lawyer, accused the program and its so-called “Vaccine Court” of corruption and inefficiency in a post on X. He has long been an outspoken critic of the program.

“I will not allow the VICP to continue to ignore its mandate and fail its mission of quickly and fairly compensating vaccine-injured individuals,” he wrote, adding he was working with Attorney General Pam Bondi. “Together, we will steer the Vaccine Court back to its original congressional intent.”

He said the structure disadvantaged claimants because the Department of Health & Human Services – which he now leads – is the defendant, as opposed to vaccine makers.

Changing the VICP would be the latest in a series of far-reaching actions by Kennedy to reshape U.S. regulation of vaccines, food and medicine.

In June, he fired all 17 members of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, a panel of vaccine experts, replacing them with 7 handpicked members, including known vaccine skeptics.

One of them earned thousands of dollars as an expert witness in litigation against Merck’s, Gardasil vaccine, court records show. Kennedy himself played an instrumental role in organizing mass litigation over the vaccine.

He also is planning to remove all the members of another advisory panel that determines what preventive health measures insurers must cover, the Wall Street Journal reported on July 25. An HHS spokesperson said Kennedy had not yet made a decision regarding the 16-member U.S. Preventive Services Task Force.

Kennedy has for years sown doubt about the safety and efficacy of vaccines. He has a history of clashing with the medical establishment and spreading misinformation about vaccines, including promoting a debunked link between vaccines and autism despite scientific evidence to the contrary.

He has also said the measles vaccine contains cells from aborted fetuses and that the mumps vaccination does not work, comments he made as the U.S. battles one of its worst outbreaks of measles in 25 years.

Kennedy made millions over the years from advocating against vaccines through case referrals, book sales, and consulting fees paid by a nonprofit he founded, according to ethics disclosures.

(Reporting by Ahmed Aboulenein; Additional reporting by Ryan Patrick Jones in Toronto; Editing by Doina Chiacu and Nia Williams)

A version of this article appeared on Medscape.com.

Publications
Topics
Sections

WASHINGTON (Reuters) - U.S. Health Secretary Robert F. Kennedy Jr. said on July 28 that he will work to “fix” the program that compensates victims of vaccine injuries, the National Vaccine Injury Compensation Program.

Kennedy, a long-time vaccine skeptic and former vaccine injury plaintiff lawyer, accused the program and its so-called “Vaccine Court” of corruption and inefficiency in a post on X. He has long been an outspoken critic of the program.

“I will not allow the VICP to continue to ignore its mandate and fail its mission of quickly and fairly compensating vaccine-injured individuals,” he wrote, adding he was working with Attorney General Pam Bondi. “Together, we will steer the Vaccine Court back to its original congressional intent.”

He said the structure disadvantaged claimants because the Department of Health & Human Services – which he now leads – is the defendant, as opposed to vaccine makers.

Changing the VICP would be the latest in a series of far-reaching actions by Kennedy to reshape U.S. regulation of vaccines, food and medicine.

In June, he fired all 17 members of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, a panel of vaccine experts, replacing them with 7 handpicked members, including known vaccine skeptics.

One of them earned thousands of dollars as an expert witness in litigation against Merck’s, Gardasil vaccine, court records show. Kennedy himself played an instrumental role in organizing mass litigation over the vaccine.

He also is planning to remove all the members of another advisory panel that determines what preventive health measures insurers must cover, the Wall Street Journal reported on July 25. An HHS spokesperson said Kennedy had not yet made a decision regarding the 16-member U.S. Preventive Services Task Force.

Kennedy has for years sown doubt about the safety and efficacy of vaccines. He has a history of clashing with the medical establishment and spreading misinformation about vaccines, including promoting a debunked link between vaccines and autism despite scientific evidence to the contrary.

He has also said the measles vaccine contains cells from aborted fetuses and that the mumps vaccination does not work, comments he made as the U.S. battles one of its worst outbreaks of measles in 25 years.

Kennedy made millions over the years from advocating against vaccines through case referrals, book sales, and consulting fees paid by a nonprofit he founded, according to ethics disclosures.

(Reporting by Ahmed Aboulenein; Additional reporting by Ryan Patrick Jones in Toronto; Editing by Doina Chiacu and Nia Williams)

A version of this article appeared on Medscape.com.

WASHINGTON (Reuters) - U.S. Health Secretary Robert F. Kennedy Jr. said on July 28 that he will work to “fix” the program that compensates victims of vaccine injuries, the National Vaccine Injury Compensation Program.

Kennedy, a long-time vaccine skeptic and former vaccine injury plaintiff lawyer, accused the program and its so-called “Vaccine Court” of corruption and inefficiency in a post on X. He has long been an outspoken critic of the program.

“I will not allow the VICP to continue to ignore its mandate and fail its mission of quickly and fairly compensating vaccine-injured individuals,” he wrote, adding he was working with Attorney General Pam Bondi. “Together, we will steer the Vaccine Court back to its original congressional intent.”

He said the structure disadvantaged claimants because the Department of Health & Human Services – which he now leads – is the defendant, as opposed to vaccine makers.

Changing the VICP would be the latest in a series of far-reaching actions by Kennedy to reshape U.S. regulation of vaccines, food and medicine.

In June, he fired all 17 members of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, a panel of vaccine experts, replacing them with 7 handpicked members, including known vaccine skeptics.

One of them earned thousands of dollars as an expert witness in litigation against Merck’s, Gardasil vaccine, court records show. Kennedy himself played an instrumental role in organizing mass litigation over the vaccine.

He also is planning to remove all the members of another advisory panel that determines what preventive health measures insurers must cover, the Wall Street Journal reported on July 25. An HHS spokesperson said Kennedy had not yet made a decision regarding the 16-member U.S. Preventive Services Task Force.

Kennedy has for years sown doubt about the safety and efficacy of vaccines. He has a history of clashing with the medical establishment and spreading misinformation about vaccines, including promoting a debunked link between vaccines and autism despite scientific evidence to the contrary.

He has also said the measles vaccine contains cells from aborted fetuses and that the mumps vaccination does not work, comments he made as the U.S. battles one of its worst outbreaks of measles in 25 years.

Kennedy made millions over the years from advocating against vaccines through case referrals, book sales, and consulting fees paid by a nonprofit he founded, according to ethics disclosures.

(Reporting by Ahmed Aboulenein; Additional reporting by Ryan Patrick Jones in Toronto; Editing by Doina Chiacu and Nia Williams)

A version of this article appeared on Medscape.com.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Rurality and Age May Shape Phone-Only Mental Health Care Access Among Veterans

Article Type
Changed

TOPLINE:

Patients living in rural areas and those aged ≥ 65 y had increased odds of receiving mental health care exclusively by phone.

METHODOLOGY:

  • Researchers explored factors linked to receiving phone-only mental health care among patients within the Department of Veterans Affairs.
  • They included data for 1,156,146 veteran patients with at least one mental health-specific outpatient encounter between October 2021 and September 2022 and at least one between October 2022 and September 2023.
  • Patients were categorized as those who received care through phone only (n = 49,125) and those who received care through other methods (n = 1,107,021. Care was received exclusively through video (6.39%), in-person (6.63%), or a combination of in-person, video, and/or phone (86.98%).
  • Demographic and clinical predictors, including rurality, age, sex, race, ethnicity, and the number of mental health diagnoses (< 3 vs ≥ 3), were evaluated.

TAKEAWAY:

  • The phone-only group had a mean of 6.27 phone visits, whereas those who received care through other methods had a mean of 4.79 phone visits.
  • Highly rural patients had 1.50 times higher odds of receiving phone-only mental health care than their urban counterparts (adjusted odds ratio [aOR], 1.50; P < .0001).
  • Patients aged 65 years or older were more than twice as likely to receive phone-only care than those younger than 30 years (aOR, ≥ 2.17; P < .0001).
  • Having fewer than three mental health diagnoses and more than 50% of mental health visits conducted by medical providers was associated with higher odds of receiving mental health care exclusively by phone (aORs, 2.03 and 1.87, respectively; P < .0001).

IN PRACTICE:

“The results of this work help to characterize the phone-only patient population and can serve to inform future implementation efforts to ensure that patients are receiving care via the modality that best meets their needs,” the authors wrote.

SOURCE:

This study was led by Samantha L. Connolly, PhD, at the VA Boston Healthcare System in Boston. It was published online in The Journal of Rural Health.

LIMITATIONS:

This study focused on a veteran population which may limit the generalizability of the findings to other groups. Additionally, its cross-sectional design restricted the ability to determine cause-and-effect relationships between factors and phone-only care.

DISCLOSURES:

This study was supported by the US Department of Veterans Affairs. The authors declared having no conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

A version of this article first appeared on Medscape.com.

Publications
Topics
Sections

TOPLINE:

Patients living in rural areas and those aged ≥ 65 y had increased odds of receiving mental health care exclusively by phone.

METHODOLOGY:

  • Researchers explored factors linked to receiving phone-only mental health care among patients within the Department of Veterans Affairs.
  • They included data for 1,156,146 veteran patients with at least one mental health-specific outpatient encounter between October 2021 and September 2022 and at least one between October 2022 and September 2023.
  • Patients were categorized as those who received care through phone only (n = 49,125) and those who received care through other methods (n = 1,107,021. Care was received exclusively through video (6.39%), in-person (6.63%), or a combination of in-person, video, and/or phone (86.98%).
  • Demographic and clinical predictors, including rurality, age, sex, race, ethnicity, and the number of mental health diagnoses (< 3 vs ≥ 3), were evaluated.

TAKEAWAY:

  • The phone-only group had a mean of 6.27 phone visits, whereas those who received care through other methods had a mean of 4.79 phone visits.
  • Highly rural patients had 1.50 times higher odds of receiving phone-only mental health care than their urban counterparts (adjusted odds ratio [aOR], 1.50; P < .0001).
  • Patients aged 65 years or older were more than twice as likely to receive phone-only care than those younger than 30 years (aOR, ≥ 2.17; P < .0001).
  • Having fewer than three mental health diagnoses and more than 50% of mental health visits conducted by medical providers was associated with higher odds of receiving mental health care exclusively by phone (aORs, 2.03 and 1.87, respectively; P < .0001).

IN PRACTICE:

“The results of this work help to characterize the phone-only patient population and can serve to inform future implementation efforts to ensure that patients are receiving care via the modality that best meets their needs,” the authors wrote.

SOURCE:

This study was led by Samantha L. Connolly, PhD, at the VA Boston Healthcare System in Boston. It was published online in The Journal of Rural Health.

LIMITATIONS:

This study focused on a veteran population which may limit the generalizability of the findings to other groups. Additionally, its cross-sectional design restricted the ability to determine cause-and-effect relationships between factors and phone-only care.

DISCLOSURES:

This study was supported by the US Department of Veterans Affairs. The authors declared having no conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

A version of this article first appeared on Medscape.com.

TOPLINE:

Patients living in rural areas and those aged ≥ 65 y had increased odds of receiving mental health care exclusively by phone.

METHODOLOGY:

  • Researchers explored factors linked to receiving phone-only mental health care among patients within the Department of Veterans Affairs.
  • They included data for 1,156,146 veteran patients with at least one mental health-specific outpatient encounter between October 2021 and September 2022 and at least one between October 2022 and September 2023.
  • Patients were categorized as those who received care through phone only (n = 49,125) and those who received care through other methods (n = 1,107,021. Care was received exclusively through video (6.39%), in-person (6.63%), or a combination of in-person, video, and/or phone (86.98%).
  • Demographic and clinical predictors, including rurality, age, sex, race, ethnicity, and the number of mental health diagnoses (< 3 vs ≥ 3), were evaluated.

TAKEAWAY:

  • The phone-only group had a mean of 6.27 phone visits, whereas those who received care through other methods had a mean of 4.79 phone visits.
  • Highly rural patients had 1.50 times higher odds of receiving phone-only mental health care than their urban counterparts (adjusted odds ratio [aOR], 1.50; P < .0001).
  • Patients aged 65 years or older were more than twice as likely to receive phone-only care than those younger than 30 years (aOR, ≥ 2.17; P < .0001).
  • Having fewer than three mental health diagnoses and more than 50% of mental health visits conducted by medical providers was associated with higher odds of receiving mental health care exclusively by phone (aORs, 2.03 and 1.87, respectively; P < .0001).

IN PRACTICE:

“The results of this work help to characterize the phone-only patient population and can serve to inform future implementation efforts to ensure that patients are receiving care via the modality that best meets their needs,” the authors wrote.

SOURCE:

This study was led by Samantha L. Connolly, PhD, at the VA Boston Healthcare System in Boston. It was published online in The Journal of Rural Health.

LIMITATIONS:

This study focused on a veteran population which may limit the generalizability of the findings to other groups. Additionally, its cross-sectional design restricted the ability to determine cause-and-effect relationships between factors and phone-only care.

DISCLOSURES:

This study was supported by the US Department of Veterans Affairs. The authors declared having no conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

A version of this article first appeared on Medscape.com.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Searching for the Optimal CRC Surveillance Test

Article Type
Changed

About a third of the US population are eligible for colorectal cancer screening but aren’t up to date on screening.

Many patients are reluctant to test for colon cancer for a variety of reasons, said Jeffrey K. Lee, MD, MPH, a research scientist at the Kaiser Permanente Northern California Division of Research and an attending gastroenterologist at Kaiser Permanente San Francisco Medical Center.

“As a gastroenterologist, I strongly believe we should emphasize the importance of colorectal cancer screening. And there’s many tests available, not just a colonoscopy, to help reduce your chances of developing colorectal cancer and even dying from colorectal cancer,” said Dr. Lee. 

Many patients prefer a test that’s more convenient, that doesn’t require them to take time out of their busy schedules. “We must educate our patients that there are some noninvasive screening options that are helpful, and to be able to share with them some of the benefits, but also some of the drawbacks compared to colonoscopy and allow them to have a choice,” he advised.

Kaiser Permanente Medical Center
Dr. Jeffrey K. Lee



Dr. Lee has devoted his research to colorectal cancer screening, as well as the causes and prevention of CRC. He is a recipient of the AGA Research Scholar Award, and has in turn supported other researchers by contributing to the AGA Research Foundation. In 2012, Dr. Lee received a grant from the Sylvia Allison Kaplan Clinical Research Fund to fund a study on long-term colorectal cancer risk in patients with normal colonoscopy results.

The findings, published in JAMA Internal Medicine, determined that 10 years after a negative colonoscopy, Kaiser Permanente members had a 46% lower risk of being diagnosed with CRC and were 88% less likely to die from disease compared with patients who didn’t undergo screening.

“Furthermore, the reduced risk of developing colorectal cancer, even dying from it, persisted for more than 12 years after the examination compared with an unscreened population,” said Dr. Lee. “I firmly believe our study really supports the ten-year screening interval after a normal colonoscopy, as currently recommended by our guidelines.”

In an interview, he discussed his research efforts to find the best detection regimens for CRC, and the mentors who guided his career path as a GI scientist. 
 

Q: Why did you choose GI?

During medical school I was fortunate to work in the lab of Dr. John M. Carethers at UC San Diego. He introduced me to GI and inspired me to choose GI as a career. His mentorship was invaluable because he not only solidified my interest in GI, but also inspired me to become a physician scientist, focusing on colorectal cancer prevention and control. His amazing mentorship drew me to this field. 

Q: One of your clinical focus areas is hereditary gastrointestinal cancer syndromes. How did you become interested in this area of GI medicine? 

My interest in hereditary GI cancer syndromes stemmed from my work as a medical student in Dr. Carethers’ lab. One of my research projects was looking at certain gene mutations among patients with hereditary GI cancer syndromes, specifically, familial hamartomatous polyposis syndrome. It was through these research projects and seeing how these genetic mutations impacted their risk of developing colorectal cancer, inspired me to care for patients with hereditary GI cancer syndromes. 

 

 

Q: Have you been doing any research on the reasons why more young people are getting colon cancer? 

We recently published work looking at the potential factors that may be driving the rising rates of early onset colorectal cancer. One hypothesis that’s been floating around is antibiotic exposure in early adulthood or childhood because of its effect on the microbiome. Using our large database at Kaiser Permanente Northern California, we did not find an association between oral antibiotic use during early adulthood and the risk of early-onset colorectal cancer.

You have the usual suspects like obesity and diabetes, but it’s not explaining all that risk. While familial colorectal cancer syndromes contribute to a small proportion of early-onset colorectal, these syndromes are not increasing across generations. I really do feel it’s something in the diet or how foods are processed and environmental factors that’s driving some of the risk of early onset colorectal cancer and this should be explored further. 
 

Q: In 2018, you issued a landmark study which found an association between a 10-year follow-up after negative colonoscopy and reduced risk of disease and mortality. Has there been any updates to these findings over the last 6 years? 

We recently saw a study in JAMA Oncology of a Swedish cohort that showed a negative colonoscopy result was associated with a reduced risk of developing and even dying from colorectal cancer 15 years from that examination, compared to the general population of Sweden. I think there’s some things that we need to be cautious about regarding that study. We have to think about the comparison group that they used and the lack of information regarding the indication of the colonoscopy and the quality of the examination. So, it remains uncertain whether future guidelines are going to stretch out that 10-year interval to 15 years.

Q: What other CRC studies are you working on now? 

We have several studies that we are working on right now. One is called the PREVENT CRC study, which is looking at whether a polygenic risk score can improve risk stratification following adenoma removal for colorectal cancer prevention and tailoring post-polypectomy surveillance. This is a large observational cohort study that we have teamed up with the Fred Hutchinson Cancer Center, Erasmus University, and Kaiser Permanente Northwest to answer this important question that may have implications for personalized medicine. 

Then there’s the COOP study, funded by the Patient-Centered Outcomes Research Institute. This is looking at the best surveillance test to use among older adults 65 years and older with a history of polyps. The trial is randomizing them to either getting a colonoscopy for surveillance or annual fecal immunochemical test (FIT) for surveillance. This is to see which test is best for detecting colorectal cancer among older adults with a history of polyps.  
 

Q: Do you think FIT tests could eventually replace colonoscopy, given that it’s less invasive? 

Although FIT and other stool-based tests are less invasive and have been shown to have high accuracy for detecting colorectal cancer, I personally do not think they are going to replace colonoscopy as the most popular screening modality in the United States. Colonoscopy remains the gold standard for detecting and removing precancerous polyps and has the highest accuracy for detecting colorectal cancer. 

 

 

Q: Besides Dr. Carethers, what teacher or mentor had the greatest impact on you? 

Clinically it’s been Dr. Jonathan Terdiman from UCSF, who taught me everything I know about clinical GI, and the art of colonoscopy. In addition, Douglas A. Corley, MD, PhD, the Permanente Medical Group’s chief research officer, has made the greatest impact on my research career. He’s really taught me how to rigorously design a research study to answer important clinically relevant questions, and has given me the skill set to write NIH grants. I would not be here without these mentors who are truly giants in the field of GI.

Q: When you’re not being a GI, how do you spend your free weekend afternoons? Are you still a “Cal Bears” fan at your alma mater, UC Berkeley? 

I spend a lot of time taking my kids to their activities on the weekends. I just took my son to a Cal Bears Game Day, which was hosted by ESPN at Berkeley.

Dr. Lee
Dr. Jeffrey K. Lee, a graduate of the University of California, Berkeley, is pictured here with his son at a 2024 Cal football game.

It was an incredible experience hearing sports analyst Pat McAfee lead all the Cal chants, seeing Nick Saban from the University of Alabama take off his red tie and replace it with a Cal Bears tie, and watching a Cal student win a hundred thousand dollars by kicking a football through the goal posts wearing checkered vans. 

Lightning Round

Texting or talking?

Text

Favorite breakfast?

Taiwanese breakfast



Place you most want to travel to?

Japan



Favorite junk food?

Trader Joe’s chili lime chips



Favorite season?

Springtime, baseball season



Favorite ice cream flavor?

Mint chocolate chip



How many cups of coffee do you drink per day?

2-3



Last movie you watched?

Oppenheimer 



Best place you ever went on vacation?

Hawaii



If you weren’t a gastroenterologist, what would you be?

Barber



Best Halloween costume you ever wore?

SpongeBob SquarePants



Favorite sport?

Tennis

What song do you have to sing along with when you hear it?

Any classic 80s song



Introvert or extrovert?

Introvert

Publications
Topics
Sections

About a third of the US population are eligible for colorectal cancer screening but aren’t up to date on screening.

Many patients are reluctant to test for colon cancer for a variety of reasons, said Jeffrey K. Lee, MD, MPH, a research scientist at the Kaiser Permanente Northern California Division of Research and an attending gastroenterologist at Kaiser Permanente San Francisco Medical Center.

“As a gastroenterologist, I strongly believe we should emphasize the importance of colorectal cancer screening. And there’s many tests available, not just a colonoscopy, to help reduce your chances of developing colorectal cancer and even dying from colorectal cancer,” said Dr. Lee. 

Many patients prefer a test that’s more convenient, that doesn’t require them to take time out of their busy schedules. “We must educate our patients that there are some noninvasive screening options that are helpful, and to be able to share with them some of the benefits, but also some of the drawbacks compared to colonoscopy and allow them to have a choice,” he advised.

Kaiser Permanente Medical Center
Dr. Jeffrey K. Lee



Dr. Lee has devoted his research to colorectal cancer screening, as well as the causes and prevention of CRC. He is a recipient of the AGA Research Scholar Award, and has in turn supported other researchers by contributing to the AGA Research Foundation. In 2012, Dr. Lee received a grant from the Sylvia Allison Kaplan Clinical Research Fund to fund a study on long-term colorectal cancer risk in patients with normal colonoscopy results.

The findings, published in JAMA Internal Medicine, determined that 10 years after a negative colonoscopy, Kaiser Permanente members had a 46% lower risk of being diagnosed with CRC and were 88% less likely to die from disease compared with patients who didn’t undergo screening.

“Furthermore, the reduced risk of developing colorectal cancer, even dying from it, persisted for more than 12 years after the examination compared with an unscreened population,” said Dr. Lee. “I firmly believe our study really supports the ten-year screening interval after a normal colonoscopy, as currently recommended by our guidelines.”

In an interview, he discussed his research efforts to find the best detection regimens for CRC, and the mentors who guided his career path as a GI scientist. 
 

Q: Why did you choose GI?

During medical school I was fortunate to work in the lab of Dr. John M. Carethers at UC San Diego. He introduced me to GI and inspired me to choose GI as a career. His mentorship was invaluable because he not only solidified my interest in GI, but also inspired me to become a physician scientist, focusing on colorectal cancer prevention and control. His amazing mentorship drew me to this field. 

Q: One of your clinical focus areas is hereditary gastrointestinal cancer syndromes. How did you become interested in this area of GI medicine? 

My interest in hereditary GI cancer syndromes stemmed from my work as a medical student in Dr. Carethers’ lab. One of my research projects was looking at certain gene mutations among patients with hereditary GI cancer syndromes, specifically, familial hamartomatous polyposis syndrome. It was through these research projects and seeing how these genetic mutations impacted their risk of developing colorectal cancer, inspired me to care for patients with hereditary GI cancer syndromes. 

 

 

Q: Have you been doing any research on the reasons why more young people are getting colon cancer? 

We recently published work looking at the potential factors that may be driving the rising rates of early onset colorectal cancer. One hypothesis that’s been floating around is antibiotic exposure in early adulthood or childhood because of its effect on the microbiome. Using our large database at Kaiser Permanente Northern California, we did not find an association between oral antibiotic use during early adulthood and the risk of early-onset colorectal cancer.

You have the usual suspects like obesity and diabetes, but it’s not explaining all that risk. While familial colorectal cancer syndromes contribute to a small proportion of early-onset colorectal, these syndromes are not increasing across generations. I really do feel it’s something in the diet or how foods are processed and environmental factors that’s driving some of the risk of early onset colorectal cancer and this should be explored further. 
 

Q: In 2018, you issued a landmark study which found an association between a 10-year follow-up after negative colonoscopy and reduced risk of disease and mortality. Has there been any updates to these findings over the last 6 years? 

We recently saw a study in JAMA Oncology of a Swedish cohort that showed a negative colonoscopy result was associated with a reduced risk of developing and even dying from colorectal cancer 15 years from that examination, compared to the general population of Sweden. I think there’s some things that we need to be cautious about regarding that study. We have to think about the comparison group that they used and the lack of information regarding the indication of the colonoscopy and the quality of the examination. So, it remains uncertain whether future guidelines are going to stretch out that 10-year interval to 15 years.

Q: What other CRC studies are you working on now? 

We have several studies that we are working on right now. One is called the PREVENT CRC study, which is looking at whether a polygenic risk score can improve risk stratification following adenoma removal for colorectal cancer prevention and tailoring post-polypectomy surveillance. This is a large observational cohort study that we have teamed up with the Fred Hutchinson Cancer Center, Erasmus University, and Kaiser Permanente Northwest to answer this important question that may have implications for personalized medicine. 

Then there’s the COOP study, funded by the Patient-Centered Outcomes Research Institute. This is looking at the best surveillance test to use among older adults 65 years and older with a history of polyps. The trial is randomizing them to either getting a colonoscopy for surveillance or annual fecal immunochemical test (FIT) for surveillance. This is to see which test is best for detecting colorectal cancer among older adults with a history of polyps.  
 

Q: Do you think FIT tests could eventually replace colonoscopy, given that it’s less invasive? 

Although FIT and other stool-based tests are less invasive and have been shown to have high accuracy for detecting colorectal cancer, I personally do not think they are going to replace colonoscopy as the most popular screening modality in the United States. Colonoscopy remains the gold standard for detecting and removing precancerous polyps and has the highest accuracy for detecting colorectal cancer. 

 

 

Q: Besides Dr. Carethers, what teacher or mentor had the greatest impact on you? 

Clinically it’s been Dr. Jonathan Terdiman from UCSF, who taught me everything I know about clinical GI, and the art of colonoscopy. In addition, Douglas A. Corley, MD, PhD, the Permanente Medical Group’s chief research officer, has made the greatest impact on my research career. He’s really taught me how to rigorously design a research study to answer important clinically relevant questions, and has given me the skill set to write NIH grants. I would not be here without these mentors who are truly giants in the field of GI.

Q: When you’re not being a GI, how do you spend your free weekend afternoons? Are you still a “Cal Bears” fan at your alma mater, UC Berkeley? 

I spend a lot of time taking my kids to their activities on the weekends. I just took my son to a Cal Bears Game Day, which was hosted by ESPN at Berkeley.

Dr. Lee
Dr. Jeffrey K. Lee, a graduate of the University of California, Berkeley, is pictured here with his son at a 2024 Cal football game.

It was an incredible experience hearing sports analyst Pat McAfee lead all the Cal chants, seeing Nick Saban from the University of Alabama take off his red tie and replace it with a Cal Bears tie, and watching a Cal student win a hundred thousand dollars by kicking a football through the goal posts wearing checkered vans. 

Lightning Round

Texting or talking?

Text

Favorite breakfast?

Taiwanese breakfast



Place you most want to travel to?

Japan



Favorite junk food?

Trader Joe’s chili lime chips



Favorite season?

Springtime, baseball season



Favorite ice cream flavor?

Mint chocolate chip



How many cups of coffee do you drink per day?

2-3



Last movie you watched?

Oppenheimer 



Best place you ever went on vacation?

Hawaii



If you weren’t a gastroenterologist, what would you be?

Barber



Best Halloween costume you ever wore?

SpongeBob SquarePants



Favorite sport?

Tennis

What song do you have to sing along with when you hear it?

Any classic 80s song



Introvert or extrovert?

Introvert

About a third of the US population are eligible for colorectal cancer screening but aren’t up to date on screening.

Many patients are reluctant to test for colon cancer for a variety of reasons, said Jeffrey K. Lee, MD, MPH, a research scientist at the Kaiser Permanente Northern California Division of Research and an attending gastroenterologist at Kaiser Permanente San Francisco Medical Center.

“As a gastroenterologist, I strongly believe we should emphasize the importance of colorectal cancer screening. And there’s many tests available, not just a colonoscopy, to help reduce your chances of developing colorectal cancer and even dying from colorectal cancer,” said Dr. Lee. 

Many patients prefer a test that’s more convenient, that doesn’t require them to take time out of their busy schedules. “We must educate our patients that there are some noninvasive screening options that are helpful, and to be able to share with them some of the benefits, but also some of the drawbacks compared to colonoscopy and allow them to have a choice,” he advised.

Kaiser Permanente Medical Center
Dr. Jeffrey K. Lee



Dr. Lee has devoted his research to colorectal cancer screening, as well as the causes and prevention of CRC. He is a recipient of the AGA Research Scholar Award, and has in turn supported other researchers by contributing to the AGA Research Foundation. In 2012, Dr. Lee received a grant from the Sylvia Allison Kaplan Clinical Research Fund to fund a study on long-term colorectal cancer risk in patients with normal colonoscopy results.

The findings, published in JAMA Internal Medicine, determined that 10 years after a negative colonoscopy, Kaiser Permanente members had a 46% lower risk of being diagnosed with CRC and were 88% less likely to die from disease compared with patients who didn’t undergo screening.

“Furthermore, the reduced risk of developing colorectal cancer, even dying from it, persisted for more than 12 years after the examination compared with an unscreened population,” said Dr. Lee. “I firmly believe our study really supports the ten-year screening interval after a normal colonoscopy, as currently recommended by our guidelines.”

In an interview, he discussed his research efforts to find the best detection regimens for CRC, and the mentors who guided his career path as a GI scientist. 
 

Q: Why did you choose GI?

During medical school I was fortunate to work in the lab of Dr. John M. Carethers at UC San Diego. He introduced me to GI and inspired me to choose GI as a career. His mentorship was invaluable because he not only solidified my interest in GI, but also inspired me to become a physician scientist, focusing on colorectal cancer prevention and control. His amazing mentorship drew me to this field. 

Q: One of your clinical focus areas is hereditary gastrointestinal cancer syndromes. How did you become interested in this area of GI medicine? 

My interest in hereditary GI cancer syndromes stemmed from my work as a medical student in Dr. Carethers’ lab. One of my research projects was looking at certain gene mutations among patients with hereditary GI cancer syndromes, specifically, familial hamartomatous polyposis syndrome. It was through these research projects and seeing how these genetic mutations impacted their risk of developing colorectal cancer, inspired me to care for patients with hereditary GI cancer syndromes. 

 

 

Q: Have you been doing any research on the reasons why more young people are getting colon cancer? 

We recently published work looking at the potential factors that may be driving the rising rates of early onset colorectal cancer. One hypothesis that’s been floating around is antibiotic exposure in early adulthood or childhood because of its effect on the microbiome. Using our large database at Kaiser Permanente Northern California, we did not find an association between oral antibiotic use during early adulthood and the risk of early-onset colorectal cancer.

You have the usual suspects like obesity and diabetes, but it’s not explaining all that risk. While familial colorectal cancer syndromes contribute to a small proportion of early-onset colorectal, these syndromes are not increasing across generations. I really do feel it’s something in the diet or how foods are processed and environmental factors that’s driving some of the risk of early onset colorectal cancer and this should be explored further. 
 

Q: In 2018, you issued a landmark study which found an association between a 10-year follow-up after negative colonoscopy and reduced risk of disease and mortality. Has there been any updates to these findings over the last 6 years? 

We recently saw a study in JAMA Oncology of a Swedish cohort that showed a negative colonoscopy result was associated with a reduced risk of developing and even dying from colorectal cancer 15 years from that examination, compared to the general population of Sweden. I think there’s some things that we need to be cautious about regarding that study. We have to think about the comparison group that they used and the lack of information regarding the indication of the colonoscopy and the quality of the examination. So, it remains uncertain whether future guidelines are going to stretch out that 10-year interval to 15 years.

Q: What other CRC studies are you working on now? 

We have several studies that we are working on right now. One is called the PREVENT CRC study, which is looking at whether a polygenic risk score can improve risk stratification following adenoma removal for colorectal cancer prevention and tailoring post-polypectomy surveillance. This is a large observational cohort study that we have teamed up with the Fred Hutchinson Cancer Center, Erasmus University, and Kaiser Permanente Northwest to answer this important question that may have implications for personalized medicine. 

Then there’s the COOP study, funded by the Patient-Centered Outcomes Research Institute. This is looking at the best surveillance test to use among older adults 65 years and older with a history of polyps. The trial is randomizing them to either getting a colonoscopy for surveillance or annual fecal immunochemical test (FIT) for surveillance. This is to see which test is best for detecting colorectal cancer among older adults with a history of polyps.  
 

Q: Do you think FIT tests could eventually replace colonoscopy, given that it’s less invasive? 

Although FIT and other stool-based tests are less invasive and have been shown to have high accuracy for detecting colorectal cancer, I personally do not think they are going to replace colonoscopy as the most popular screening modality in the United States. Colonoscopy remains the gold standard for detecting and removing precancerous polyps and has the highest accuracy for detecting colorectal cancer. 

 

 

Q: Besides Dr. Carethers, what teacher or mentor had the greatest impact on you? 

Clinically it’s been Dr. Jonathan Terdiman from UCSF, who taught me everything I know about clinical GI, and the art of colonoscopy. In addition, Douglas A. Corley, MD, PhD, the Permanente Medical Group’s chief research officer, has made the greatest impact on my research career. He’s really taught me how to rigorously design a research study to answer important clinically relevant questions, and has given me the skill set to write NIH grants. I would not be here without these mentors who are truly giants in the field of GI.

Q: When you’re not being a GI, how do you spend your free weekend afternoons? Are you still a “Cal Bears” fan at your alma mater, UC Berkeley? 

I spend a lot of time taking my kids to their activities on the weekends. I just took my son to a Cal Bears Game Day, which was hosted by ESPN at Berkeley.

Dr. Lee
Dr. Jeffrey K. Lee, a graduate of the University of California, Berkeley, is pictured here with his son at a 2024 Cal football game.

It was an incredible experience hearing sports analyst Pat McAfee lead all the Cal chants, seeing Nick Saban from the University of Alabama take off his red tie and replace it with a Cal Bears tie, and watching a Cal student win a hundred thousand dollars by kicking a football through the goal posts wearing checkered vans. 

Lightning Round

Texting or talking?

Text

Favorite breakfast?

Taiwanese breakfast



Place you most want to travel to?

Japan



Favorite junk food?

Trader Joe’s chili lime chips



Favorite season?

Springtime, baseball season



Favorite ice cream flavor?

Mint chocolate chip



How many cups of coffee do you drink per day?

2-3



Last movie you watched?

Oppenheimer 



Best place you ever went on vacation?

Hawaii



If you weren’t a gastroenterologist, what would you be?

Barber



Best Halloween costume you ever wore?

SpongeBob SquarePants



Favorite sport?

Tennis

What song do you have to sing along with when you hear it?

Any classic 80s song



Introvert or extrovert?

Introvert

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Dermatologic Implications of Prickly Pear Cacti (Opuntia)

Article Type
Changed
Display Headline

Dermatologic Implications of Prickly Pear Cacti (Opuntia)

The genus of flowering plants commonly known as prickly pear cacti (Opuntia) or sabra are native to the Americas but are naturalized in many parts of the world, particularly southwest Asia and Sicily, Italy, where they are grown commercially and commonly are seen growing on rocky hillsides. (Figure 1). A prickly pear cactus has paddles that represent modified stems, and the spines are modified leaves (Figure 2). Its bright red or yellow flowers, dark-red fruit, low water requirement, and adaptability to poor-quality soil make it an attractive plant for landscaping and an important agricultural crop in many parts of the world, including the United States, Mexico, and Southern Europe. The prickly pear fruit is tasty but loaded with seeds and often is eaten fresh or used to make jam. The paddles are sometimes cut into strips, breaded or battered, and fried. The spines are easily embedded in skin and are an important cause of dermatitis.

Elston-BB-1
FIGURE 1. Opuntia species (prickly pear) are seen growing on rocky hillsides.
CT117002055-Fig2_AB
FIGURE 2. A and B, Opuntia species (flowering prickly pear cacti) have paddles that represent modified stems, and the spines are modified leaves.

Identifying Features

Opuntia species are found in both warm and temperate zones and grow well in arid climates. Like other cacti, they are distinguished by their water-hoarding stems and glochids (needlelike modified leaves). In prickly pears, the stems flatten to leaflike paddles that alternate in direction. Photosynthesis occurs in the stem tissues, while modified leaves (spines) are purely for defense against predators and unsuspecting humans. Opuntia species are easily identified by their broad flattened stems and dark-red fruits, both of which bear glochids (Figures 3-5).

Elston-BB-3
FIGURE 3. Broad flattened stems and dark-red fruits on the Opuntia species (prickly pear).
Elston-BB-4
FIGURE 4. Opuntia ficus-indica (L.) Miller (prickly pear) is easily identified by its broad, flattened stems and dark-red fruits.
Elston-BB-5
FIGURE 5. Opuntia ficus-indica (L.) Miller (prickly pear) glochids.

Dermatologic Implications of Prickly Pear Injury

Prickly pear spines are very small, sharp, and difficult to see. They embed in the skin in great numbers when the plant or its fruit are handled by unsuspecting humans and have a tendency to burrow into soft tissue and underlying structures. It is very difficult to remove prickly pear spines with forceps, and attempts to do so often drive them deeper into the skin.1 Better results are obtained by tape stripping or using water-activated cosmetic pore strips.

Cactus spine injuries may lead to mucoceles of the oral mucosa and sinuses, especially in individuals who attempt to bite into the fruit without first scorching the spines with a blow torch.2 Inflammatory responses to the embedded spines are common and often result in prolonged erythematous inflammatory papules at sites of injury. Recalcitrant dermatitis and edema of underlying tissues typically occur near the point of entry of a prickly pear spine and extend to areas where the spine migrates.3,4 Individuals who casually brush up against the plant may not be aware that they have been inoculated with the spines and may not relate the prior accidental contact with the onset of erythematous papules and edema that occurs days later. Biopsy may reveal the prickly pear spines or a granulomatous reaction pattern within the dermis. Linear patterns of necrosis surrounded by palisading histiocytes may be noted, representing the tract of the inoculation injury.

If identified in tissue, glochids are variably refractile and measure 40 to 70 µm in diameter. Glochids initiate a delayed-type hypersensitivity and foreign body response. A T-helper 1 cytokine signal is typical, and there may be a secondary influx of neutrophils, but tissue eosinophilia is uncommon. Systemic inflammation also has been reported, including eosinophilic cholangitis without biliary stricture5 and septic and aseptic arthritis near the site of leaf puncture and at distant sites.6,7 Allergic contact dermatitis has been reported due to contact with the fruit of the plant and can be confirmed by patch testing.8,9

Potential Medicinal Benefits

Prickly pear cacti have shown potential medicinal properties. While the spines may produce intense inflammation when embedded in the skin, extracts of the fruit and leaf juices have shown anti-inflammatory properties. Various vesicle and polysaccharide extracts of Opuntia cacti have been shown to reduce environmental and chemical stressors associated with open wounds.10-12 Preclinical studies also have suggested that they could be helpful in speeding the wound-healing process when applied topically. Opuntia species also have shown promise in reducing hyperpigmentation after topical application.13 Preliminary data in animals also have suggested that oral administration of the fruit may slow kidney deterioration in patients with diabetes.14 Following tissue penetration by the spines, Opuntia extracts have demonstrated the ability to prevent calcium deposition in soft tissue.15 Similar preliminary data also have suggested that Opuntia extracts may reduce toxicity from cadmium, chromium, methotrexate, and acetaminophen.16-19 Extracts from the peel of the red pitaya (Hylocereus polyrhizus), a closely related cactus, have been studied for their potential to prevent the advance of alcohol-associated liver disease, suggesting that studies evaluating the benefits of prickly pear cacti and related species may be worth pursuing.20

Final Thoughts

Prickly pear cacti have the potential to act as both friend and foe. The flowers and fruit are beautiful, and the plant is well adapted to xeriscape gardens in areas under perpetual water restriction. The fruit and flesh are edible if handled properly, and prickly pear jam is delicious. While the spines are capable of inflicting local injury and migrating to internal sites, causing arthritis and other deep tissue injury, extracts of the fruit and stems have potential uses for their anti-inflammatory effects and ability to protect against toxic injury. Further studies are needed to evaluate the therapeutic potential of Opuntia and related species.

References
  1. Ford AM, Haywood ST, Gallo DR. Novel method for removing embedded cactus spines in the emergency department. Case Rep Emerg Med. 2019;2019:6062531.
  2. Patel D, Clarkson J, Amirapu S. Frontal sinus post-traumatic mucocele secondary to a cactus spine. N Z Med J. 2020;133:112-115.
  3. Magro C, Lipner S. Sabra dermatitis: combined features of delayed hypersensitivity and foreign body reaction to implanted glochidia. Dermatol Online J. 2020;26:13030/qt2157f9g0.
  4. Ruini C, von Braunmühl T, Ruzicka T, et al. Granulomatous reaction after cholla cactus spine injury. Cutis. 2020;105:143-145;E2.
  5. Kitagawa S, Okamura K, Ichihara S, et al. Eosinophilic cholangitis without biliary stricture after cactus spine injury. Am J Gastroenterol. 2022;117:1731.
  6. Ontiveros ST, Minns AB. Accidental arthrotomy causing aseptic monoarthritis due to agave sap: a case report. Clin Pract Cases Emerg Med. 2021;5:246-248.
  7. Kim S, Baradia H, Sambasivan A. The use of ultrasonography in expediting septic joint identification and treatment: a case report. Am J Phys Med Rehabil. 2020;99:449-451.
  8. Yoon HJ, Won CH, Moon SE. Allergic contact dermatitis due to Opuntia ficus-indica var. saboten. Contact Dermatitis. 2004;51:311-312.
  9. Bonamonte D, Foti C, Gullo G, et al. Plant contact dermatitis. In: Angelini G, Bonamonte D, Foti C, eds. Clinical Contact Dermatitis. 2021; Springer, Cham. doi:10.1007/978-3-030-49332-5_16
  10. Valentino A, Conte R, Bousta D, et al. Extracellular vesicles derived from Opuntia ficus-indica fruit (OFI-EVs) speed up the normal wound healing processes by modulating cellular responses. Int J Mol Sci. 2024;25:7103.
  11. Das IJ, Bal T. Evaluation of Opuntia-carrageenan superporous hydrogel (OPM-CRG SPH) as an effective biomaterial for drug release and tissue scaffold. Int J Biol Macromol. 2024;256(Pt 2):128503.
  12. Adjafre BL, Lima IC, Alves APNN, et al. Anti-inflammatory and healing effect of the polysaccharidic extract of Opuntia ficus-indica cladodes in cutaneous excisional wounds in rats. Int J Exp Pathol. 2024;105:33-44.
  13. Chiu CS, Cheng YT, Chan YJ, et al. Mechanism and inhibitory effects of cactus (Opuntia dillenii) extract on melanocytes and its potential application for whitening cosmetics. Sci Rep. 2023;13:501.
  14. Sutariya B, Saraf M. Betanin, isolated from fruits of Opuntia elatior Mill attenuates renal fibrosis in diabetic rats through regulating oxidative stress and TGF-β pathway. J Ethnopharmacol. 2017;198:432-443.
  15. Partovi N, Ebadzadeh MR, Fatemi SJ, et al. Effect of fruit extract on renal stone formation and kidney injury in rats. Nat Prod Res. 2018;32:1180-1183.
  16. Zhu X, Athmouni K. HPLC analysis and the antioxidant and preventive actions of Opuntia stricta juice extract against hepato-nephrotoxicity and testicular injury induced by cadmium exposure. Molecules. 2022;27:4972.
  17. Akacha A, Badraoui R, Rebai T, et al. Effect of Opuntia ficus indica extract on methotrexate-induced testicular injury: a biochemical, docking and histological study. J Biomol Struct Dyn. 2022;40:4341-4351.
  18. González-Ponce HA, Martínez-Saldaña MC, Tepper PG, et al. Betacyanins, major components in Opuntia red-purple fruits, protect against acetaminophen-induced acute liver failure. Food Res Int. 2020;137:109461.
  19. Akacha A, Rebai T, Zourgui L, et al. Preventive effect of ethanolic extract of cactus (Opuntia ficus-indica) cladodes on methotrexate-induced oxidative damage of the small intestine in Wistar rats. J Cancer Res Ther. 2018;14(Suppl):S779-S784.
  20. Yeh WJ, Tsai CC, Ko J, et al. Hylocereus polyrhizus peel extract retards alcoholic liver disease progression by modulating oxidative stress and inflammatory responses in C57BL/6 mice. Nutrients. 2020;12:3884.
Article PDF
Author and Disclosure Information

Nathaniel C. Elston is from the Department of Environmental and Sustainability Studies, College of Charleston, South Carolina. Dr. Elston is from the Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston.

The authors have relevant financial disclosures to report.

Correspondence: Dirk M. Elston, MD, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, MSC 578, 135 Rutledge Ave, 11th Floor, Charleston, SC 29425-5780 (elstond@musc.edu).

Cutis. 2026 February;117(2):55-57. doi:10.12788/cutis.1334

Issue
Cutis - 117(2)
Publications
Topics
Page Number
55-57
Sections
Author and Disclosure Information

Nathaniel C. Elston is from the Department of Environmental and Sustainability Studies, College of Charleston, South Carolina. Dr. Elston is from the Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston.

The authors have relevant financial disclosures to report.

Correspondence: Dirk M. Elston, MD, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, MSC 578, 135 Rutledge Ave, 11th Floor, Charleston, SC 29425-5780 (elstond@musc.edu).

Cutis. 2026 February;117(2):55-57. doi:10.12788/cutis.1334

Author and Disclosure Information

Nathaniel C. Elston is from the Department of Environmental and Sustainability Studies, College of Charleston, South Carolina. Dr. Elston is from the Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston.

The authors have relevant financial disclosures to report.

Correspondence: Dirk M. Elston, MD, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, MSC 578, 135 Rutledge Ave, 11th Floor, Charleston, SC 29425-5780 (elstond@musc.edu).

Cutis. 2026 February;117(2):55-57. doi:10.12788/cutis.1334

Article PDF
Article PDF

The genus of flowering plants commonly known as prickly pear cacti (Opuntia) or sabra are native to the Americas but are naturalized in many parts of the world, particularly southwest Asia and Sicily, Italy, where they are grown commercially and commonly are seen growing on rocky hillsides. (Figure 1). A prickly pear cactus has paddles that represent modified stems, and the spines are modified leaves (Figure 2). Its bright red or yellow flowers, dark-red fruit, low water requirement, and adaptability to poor-quality soil make it an attractive plant for landscaping and an important agricultural crop in many parts of the world, including the United States, Mexico, and Southern Europe. The prickly pear fruit is tasty but loaded with seeds and often is eaten fresh or used to make jam. The paddles are sometimes cut into strips, breaded or battered, and fried. The spines are easily embedded in skin and are an important cause of dermatitis.

Elston-BB-1
FIGURE 1. Opuntia species (prickly pear) are seen growing on rocky hillsides.
CT117002055-Fig2_AB
FIGURE 2. A and B, Opuntia species (flowering prickly pear cacti) have paddles that represent modified stems, and the spines are modified leaves.

Identifying Features

Opuntia species are found in both warm and temperate zones and grow well in arid climates. Like other cacti, they are distinguished by their water-hoarding stems and glochids (needlelike modified leaves). In prickly pears, the stems flatten to leaflike paddles that alternate in direction. Photosynthesis occurs in the stem tissues, while modified leaves (spines) are purely for defense against predators and unsuspecting humans. Opuntia species are easily identified by their broad flattened stems and dark-red fruits, both of which bear glochids (Figures 3-5).

Elston-BB-3
FIGURE 3. Broad flattened stems and dark-red fruits on the Opuntia species (prickly pear).
Elston-BB-4
FIGURE 4. Opuntia ficus-indica (L.) Miller (prickly pear) is easily identified by its broad, flattened stems and dark-red fruits.
Elston-BB-5
FIGURE 5. Opuntia ficus-indica (L.) Miller (prickly pear) glochids.

Dermatologic Implications of Prickly Pear Injury

Prickly pear spines are very small, sharp, and difficult to see. They embed in the skin in great numbers when the plant or its fruit are handled by unsuspecting humans and have a tendency to burrow into soft tissue and underlying structures. It is very difficult to remove prickly pear spines with forceps, and attempts to do so often drive them deeper into the skin.1 Better results are obtained by tape stripping or using water-activated cosmetic pore strips.

Cactus spine injuries may lead to mucoceles of the oral mucosa and sinuses, especially in individuals who attempt to bite into the fruit without first scorching the spines with a blow torch.2 Inflammatory responses to the embedded spines are common and often result in prolonged erythematous inflammatory papules at sites of injury. Recalcitrant dermatitis and edema of underlying tissues typically occur near the point of entry of a prickly pear spine and extend to areas where the spine migrates.3,4 Individuals who casually brush up against the plant may not be aware that they have been inoculated with the spines and may not relate the prior accidental contact with the onset of erythematous papules and edema that occurs days later. Biopsy may reveal the prickly pear spines or a granulomatous reaction pattern within the dermis. Linear patterns of necrosis surrounded by palisading histiocytes may be noted, representing the tract of the inoculation injury.

If identified in tissue, glochids are variably refractile and measure 40 to 70 µm in diameter. Glochids initiate a delayed-type hypersensitivity and foreign body response. A T-helper 1 cytokine signal is typical, and there may be a secondary influx of neutrophils, but tissue eosinophilia is uncommon. Systemic inflammation also has been reported, including eosinophilic cholangitis without biliary stricture5 and septic and aseptic arthritis near the site of leaf puncture and at distant sites.6,7 Allergic contact dermatitis has been reported due to contact with the fruit of the plant and can be confirmed by patch testing.8,9

Potential Medicinal Benefits

Prickly pear cacti have shown potential medicinal properties. While the spines may produce intense inflammation when embedded in the skin, extracts of the fruit and leaf juices have shown anti-inflammatory properties. Various vesicle and polysaccharide extracts of Opuntia cacti have been shown to reduce environmental and chemical stressors associated with open wounds.10-12 Preclinical studies also have suggested that they could be helpful in speeding the wound-healing process when applied topically. Opuntia species also have shown promise in reducing hyperpigmentation after topical application.13 Preliminary data in animals also have suggested that oral administration of the fruit may slow kidney deterioration in patients with diabetes.14 Following tissue penetration by the spines, Opuntia extracts have demonstrated the ability to prevent calcium deposition in soft tissue.15 Similar preliminary data also have suggested that Opuntia extracts may reduce toxicity from cadmium, chromium, methotrexate, and acetaminophen.16-19 Extracts from the peel of the red pitaya (Hylocereus polyrhizus), a closely related cactus, have been studied for their potential to prevent the advance of alcohol-associated liver disease, suggesting that studies evaluating the benefits of prickly pear cacti and related species may be worth pursuing.20

Final Thoughts

Prickly pear cacti have the potential to act as both friend and foe. The flowers and fruit are beautiful, and the plant is well adapted to xeriscape gardens in areas under perpetual water restriction. The fruit and flesh are edible if handled properly, and prickly pear jam is delicious. While the spines are capable of inflicting local injury and migrating to internal sites, causing arthritis and other deep tissue injury, extracts of the fruit and stems have potential uses for their anti-inflammatory effects and ability to protect against toxic injury. Further studies are needed to evaluate the therapeutic potential of Opuntia and related species.

The genus of flowering plants commonly known as prickly pear cacti (Opuntia) or sabra are native to the Americas but are naturalized in many parts of the world, particularly southwest Asia and Sicily, Italy, where they are grown commercially and commonly are seen growing on rocky hillsides. (Figure 1). A prickly pear cactus has paddles that represent modified stems, and the spines are modified leaves (Figure 2). Its bright red or yellow flowers, dark-red fruit, low water requirement, and adaptability to poor-quality soil make it an attractive plant for landscaping and an important agricultural crop in many parts of the world, including the United States, Mexico, and Southern Europe. The prickly pear fruit is tasty but loaded with seeds and often is eaten fresh or used to make jam. The paddles are sometimes cut into strips, breaded or battered, and fried. The spines are easily embedded in skin and are an important cause of dermatitis.

Elston-BB-1
FIGURE 1. Opuntia species (prickly pear) are seen growing on rocky hillsides.
CT117002055-Fig2_AB
FIGURE 2. A and B, Opuntia species (flowering prickly pear cacti) have paddles that represent modified stems, and the spines are modified leaves.

Identifying Features

Opuntia species are found in both warm and temperate zones and grow well in arid climates. Like other cacti, they are distinguished by their water-hoarding stems and glochids (needlelike modified leaves). In prickly pears, the stems flatten to leaflike paddles that alternate in direction. Photosynthesis occurs in the stem tissues, while modified leaves (spines) are purely for defense against predators and unsuspecting humans. Opuntia species are easily identified by their broad flattened stems and dark-red fruits, both of which bear glochids (Figures 3-5).

Elston-BB-3
FIGURE 3. Broad flattened stems and dark-red fruits on the Opuntia species (prickly pear).
Elston-BB-4
FIGURE 4. Opuntia ficus-indica (L.) Miller (prickly pear) is easily identified by its broad, flattened stems and dark-red fruits.
Elston-BB-5
FIGURE 5. Opuntia ficus-indica (L.) Miller (prickly pear) glochids.

Dermatologic Implications of Prickly Pear Injury

Prickly pear spines are very small, sharp, and difficult to see. They embed in the skin in great numbers when the plant or its fruit are handled by unsuspecting humans and have a tendency to burrow into soft tissue and underlying structures. It is very difficult to remove prickly pear spines with forceps, and attempts to do so often drive them deeper into the skin.1 Better results are obtained by tape stripping or using water-activated cosmetic pore strips.

Cactus spine injuries may lead to mucoceles of the oral mucosa and sinuses, especially in individuals who attempt to bite into the fruit without first scorching the spines with a blow torch.2 Inflammatory responses to the embedded spines are common and often result in prolonged erythematous inflammatory papules at sites of injury. Recalcitrant dermatitis and edema of underlying tissues typically occur near the point of entry of a prickly pear spine and extend to areas where the spine migrates.3,4 Individuals who casually brush up against the plant may not be aware that they have been inoculated with the spines and may not relate the prior accidental contact with the onset of erythematous papules and edema that occurs days later. Biopsy may reveal the prickly pear spines or a granulomatous reaction pattern within the dermis. Linear patterns of necrosis surrounded by palisading histiocytes may be noted, representing the tract of the inoculation injury.

If identified in tissue, glochids are variably refractile and measure 40 to 70 µm in diameter. Glochids initiate a delayed-type hypersensitivity and foreign body response. A T-helper 1 cytokine signal is typical, and there may be a secondary influx of neutrophils, but tissue eosinophilia is uncommon. Systemic inflammation also has been reported, including eosinophilic cholangitis without biliary stricture5 and septic and aseptic arthritis near the site of leaf puncture and at distant sites.6,7 Allergic contact dermatitis has been reported due to contact with the fruit of the plant and can be confirmed by patch testing.8,9

Potential Medicinal Benefits

Prickly pear cacti have shown potential medicinal properties. While the spines may produce intense inflammation when embedded in the skin, extracts of the fruit and leaf juices have shown anti-inflammatory properties. Various vesicle and polysaccharide extracts of Opuntia cacti have been shown to reduce environmental and chemical stressors associated with open wounds.10-12 Preclinical studies also have suggested that they could be helpful in speeding the wound-healing process when applied topically. Opuntia species also have shown promise in reducing hyperpigmentation after topical application.13 Preliminary data in animals also have suggested that oral administration of the fruit may slow kidney deterioration in patients with diabetes.14 Following tissue penetration by the spines, Opuntia extracts have demonstrated the ability to prevent calcium deposition in soft tissue.15 Similar preliminary data also have suggested that Opuntia extracts may reduce toxicity from cadmium, chromium, methotrexate, and acetaminophen.16-19 Extracts from the peel of the red pitaya (Hylocereus polyrhizus), a closely related cactus, have been studied for their potential to prevent the advance of alcohol-associated liver disease, suggesting that studies evaluating the benefits of prickly pear cacti and related species may be worth pursuing.20

Final Thoughts

Prickly pear cacti have the potential to act as both friend and foe. The flowers and fruit are beautiful, and the plant is well adapted to xeriscape gardens in areas under perpetual water restriction. The fruit and flesh are edible if handled properly, and prickly pear jam is delicious. While the spines are capable of inflicting local injury and migrating to internal sites, causing arthritis and other deep tissue injury, extracts of the fruit and stems have potential uses for their anti-inflammatory effects and ability to protect against toxic injury. Further studies are needed to evaluate the therapeutic potential of Opuntia and related species.

References
  1. Ford AM, Haywood ST, Gallo DR. Novel method for removing embedded cactus spines in the emergency department. Case Rep Emerg Med. 2019;2019:6062531.
  2. Patel D, Clarkson J, Amirapu S. Frontal sinus post-traumatic mucocele secondary to a cactus spine. N Z Med J. 2020;133:112-115.
  3. Magro C, Lipner S. Sabra dermatitis: combined features of delayed hypersensitivity and foreign body reaction to implanted glochidia. Dermatol Online J. 2020;26:13030/qt2157f9g0.
  4. Ruini C, von Braunmühl T, Ruzicka T, et al. Granulomatous reaction after cholla cactus spine injury. Cutis. 2020;105:143-145;E2.
  5. Kitagawa S, Okamura K, Ichihara S, et al. Eosinophilic cholangitis without biliary stricture after cactus spine injury. Am J Gastroenterol. 2022;117:1731.
  6. Ontiveros ST, Minns AB. Accidental arthrotomy causing aseptic monoarthritis due to agave sap: a case report. Clin Pract Cases Emerg Med. 2021;5:246-248.
  7. Kim S, Baradia H, Sambasivan A. The use of ultrasonography in expediting septic joint identification and treatment: a case report. Am J Phys Med Rehabil. 2020;99:449-451.
  8. Yoon HJ, Won CH, Moon SE. Allergic contact dermatitis due to Opuntia ficus-indica var. saboten. Contact Dermatitis. 2004;51:311-312.
  9. Bonamonte D, Foti C, Gullo G, et al. Plant contact dermatitis. In: Angelini G, Bonamonte D, Foti C, eds. Clinical Contact Dermatitis. 2021; Springer, Cham. doi:10.1007/978-3-030-49332-5_16
  10. Valentino A, Conte R, Bousta D, et al. Extracellular vesicles derived from Opuntia ficus-indica fruit (OFI-EVs) speed up the normal wound healing processes by modulating cellular responses. Int J Mol Sci. 2024;25:7103.
  11. Das IJ, Bal T. Evaluation of Opuntia-carrageenan superporous hydrogel (OPM-CRG SPH) as an effective biomaterial for drug release and tissue scaffold. Int J Biol Macromol. 2024;256(Pt 2):128503.
  12. Adjafre BL, Lima IC, Alves APNN, et al. Anti-inflammatory and healing effect of the polysaccharidic extract of Opuntia ficus-indica cladodes in cutaneous excisional wounds in rats. Int J Exp Pathol. 2024;105:33-44.
  13. Chiu CS, Cheng YT, Chan YJ, et al. Mechanism and inhibitory effects of cactus (Opuntia dillenii) extract on melanocytes and its potential application for whitening cosmetics. Sci Rep. 2023;13:501.
  14. Sutariya B, Saraf M. Betanin, isolated from fruits of Opuntia elatior Mill attenuates renal fibrosis in diabetic rats through regulating oxidative stress and TGF-β pathway. J Ethnopharmacol. 2017;198:432-443.
  15. Partovi N, Ebadzadeh MR, Fatemi SJ, et al. Effect of fruit extract on renal stone formation and kidney injury in rats. Nat Prod Res. 2018;32:1180-1183.
  16. Zhu X, Athmouni K. HPLC analysis and the antioxidant and preventive actions of Opuntia stricta juice extract against hepato-nephrotoxicity and testicular injury induced by cadmium exposure. Molecules. 2022;27:4972.
  17. Akacha A, Badraoui R, Rebai T, et al. Effect of Opuntia ficus indica extract on methotrexate-induced testicular injury: a biochemical, docking and histological study. J Biomol Struct Dyn. 2022;40:4341-4351.
  18. González-Ponce HA, Martínez-Saldaña MC, Tepper PG, et al. Betacyanins, major components in Opuntia red-purple fruits, protect against acetaminophen-induced acute liver failure. Food Res Int. 2020;137:109461.
  19. Akacha A, Rebai T, Zourgui L, et al. Preventive effect of ethanolic extract of cactus (Opuntia ficus-indica) cladodes on methotrexate-induced oxidative damage of the small intestine in Wistar rats. J Cancer Res Ther. 2018;14(Suppl):S779-S784.
  20. Yeh WJ, Tsai CC, Ko J, et al. Hylocereus polyrhizus peel extract retards alcoholic liver disease progression by modulating oxidative stress and inflammatory responses in C57BL/6 mice. Nutrients. 2020;12:3884.
References
  1. Ford AM, Haywood ST, Gallo DR. Novel method for removing embedded cactus spines in the emergency department. Case Rep Emerg Med. 2019;2019:6062531.
  2. Patel D, Clarkson J, Amirapu S. Frontal sinus post-traumatic mucocele secondary to a cactus spine. N Z Med J. 2020;133:112-115.
  3. Magro C, Lipner S. Sabra dermatitis: combined features of delayed hypersensitivity and foreign body reaction to implanted glochidia. Dermatol Online J. 2020;26:13030/qt2157f9g0.
  4. Ruini C, von Braunmühl T, Ruzicka T, et al. Granulomatous reaction after cholla cactus spine injury. Cutis. 2020;105:143-145;E2.
  5. Kitagawa S, Okamura K, Ichihara S, et al. Eosinophilic cholangitis without biliary stricture after cactus spine injury. Am J Gastroenterol. 2022;117:1731.
  6. Ontiveros ST, Minns AB. Accidental arthrotomy causing aseptic monoarthritis due to agave sap: a case report. Clin Pract Cases Emerg Med. 2021;5:246-248.
  7. Kim S, Baradia H, Sambasivan A. The use of ultrasonography in expediting septic joint identification and treatment: a case report. Am J Phys Med Rehabil. 2020;99:449-451.
  8. Yoon HJ, Won CH, Moon SE. Allergic contact dermatitis due to Opuntia ficus-indica var. saboten. Contact Dermatitis. 2004;51:311-312.
  9. Bonamonte D, Foti C, Gullo G, et al. Plant contact dermatitis. In: Angelini G, Bonamonte D, Foti C, eds. Clinical Contact Dermatitis. 2021; Springer, Cham. doi:10.1007/978-3-030-49332-5_16
  10. Valentino A, Conte R, Bousta D, et al. Extracellular vesicles derived from Opuntia ficus-indica fruit (OFI-EVs) speed up the normal wound healing processes by modulating cellular responses. Int J Mol Sci. 2024;25:7103.
  11. Das IJ, Bal T. Evaluation of Opuntia-carrageenan superporous hydrogel (OPM-CRG SPH) as an effective biomaterial for drug release and tissue scaffold. Int J Biol Macromol. 2024;256(Pt 2):128503.
  12. Adjafre BL, Lima IC, Alves APNN, et al. Anti-inflammatory and healing effect of the polysaccharidic extract of Opuntia ficus-indica cladodes in cutaneous excisional wounds in rats. Int J Exp Pathol. 2024;105:33-44.
  13. Chiu CS, Cheng YT, Chan YJ, et al. Mechanism and inhibitory effects of cactus (Opuntia dillenii) extract on melanocytes and its potential application for whitening cosmetics. Sci Rep. 2023;13:501.
  14. Sutariya B, Saraf M. Betanin, isolated from fruits of Opuntia elatior Mill attenuates renal fibrosis in diabetic rats through regulating oxidative stress and TGF-β pathway. J Ethnopharmacol. 2017;198:432-443.
  15. Partovi N, Ebadzadeh MR, Fatemi SJ, et al. Effect of fruit extract on renal stone formation and kidney injury in rats. Nat Prod Res. 2018;32:1180-1183.
  16. Zhu X, Athmouni K. HPLC analysis and the antioxidant and preventive actions of Opuntia stricta juice extract against hepato-nephrotoxicity and testicular injury induced by cadmium exposure. Molecules. 2022;27:4972.
  17. Akacha A, Badraoui R, Rebai T, et al. Effect of Opuntia ficus indica extract on methotrexate-induced testicular injury: a biochemical, docking and histological study. J Biomol Struct Dyn. 2022;40:4341-4351.
  18. González-Ponce HA, Martínez-Saldaña MC, Tepper PG, et al. Betacyanins, major components in Opuntia red-purple fruits, protect against acetaminophen-induced acute liver failure. Food Res Int. 2020;137:109461.
  19. Akacha A, Rebai T, Zourgui L, et al. Preventive effect of ethanolic extract of cactus (Opuntia ficus-indica) cladodes on methotrexate-induced oxidative damage of the small intestine in Wistar rats. J Cancer Res Ther. 2018;14(Suppl):S779-S784.
  20. Yeh WJ, Tsai CC, Ko J, et al. Hylocereus polyrhizus peel extract retards alcoholic liver disease progression by modulating oxidative stress and inflammatory responses in C57BL/6 mice. Nutrients. 2020;12:3884.
Issue
Cutis - 117(2)
Issue
Cutis - 117(2)
Page Number
55-57
Page Number
55-57
Publications
Publications
Topics
Article Type
Display Headline

Dermatologic Implications of Prickly Pear Cacti (Opuntia)

Display Headline

Dermatologic Implications of Prickly Pear Cacti (Opuntia)

Sections
Inside the Article

Practice Points

  • Prickly pear cacti have fine spines that must be removed via scorching or mechanical means before the fruit can be handled safely.
  • Prickly pear spines that become embedded in the skin are associated with local and systemic inflammatory conditions as well as allergic contact dermatitis.
  • Preclinical studies have suggested that extracts of the prickly pear cactus could be used in medicine for their anti-inflammatory effects.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Dermatology Boards Demystified: Conquer the BASIC, CORE, and APPLIED Exams

Article Type
Changed
Display Headline

Dermatology Boards Demystified: Conquer the BASIC, CORE, and APPLIED Exams

Dermatology trainees are no strangers to standardized examinations that assess basic science and medical knowledge, from the Medical College Admission Test and the National Board of Medical Examiners Subject Examinations to the United States Medical Licensing Examination series (I know, cue the collective flashbacks!). As a dermatology resident, you will complete a series of 6 examinations, culminating with the final APPLIED Exam, which assesses a trainee's ability to apply therapeutic knowledge and clinical reasoning in scenarios relevant to the practice of general dermatology.1 This article features high-yield tips and study resources alongside test-day strategies to help you perform at your best.

The Path to Board Certification for Dermatology Trainees

After years of dedicated study in medical school, navigating the demanding match process, and completing your intern year, you have finally made it to dermatology! With the USMLE Step 3 out of the way, you are now officially able to trade in electrocardiograms for Kodachromes and dermoscopy. As a dermatology trainee, you will complete the American Board of Dermatology (ABD) Certification Pathway—a staged evaluation beginning with a BASIC Exam for first-year residents, which covers dermatology fundamentals and is proctored at your home institution.1 This exam is solely for informational purposes, and ultimately no minimum score is required for certification purposes. Subsequently, second- and third-year residents sit for 4 CORE Exam modules assessing advanced knowledge of the major clinical areas of the specialty: medical dermatology, surgical dermatology, pediatric dermatology, and dermatopathology. These exams consist of 75 to 100 multiple-choice questions per each 2-hour module and are administered either online in a private setting, via a secure online proctoring system, or at an approved testing center. The APPLIED Exam is the final component of the pathway and prioritizes clinical acumen and judgement. This 8-hour, 200-question exam is offered exclusively in person at approved testing centers to residents who have passed all 4 compulsory CORE modules and completed residency training. There is a 20-minute break between sections 1 and 2, a 60-minute break between sections 2 and 3, and a 20-minute break between sections 3 and 4.1 Following successful completion of the ABD Certification Pathway, dermatologists maintain board certification through quarterly CertLink questions, which you must complete at least 3 quarters of each year, and regular completion of focused practice improvement modules every 5 years. Additionally, one must maintain a full and unrestricted medical license in the United States or Canada and pay an annual fee of $150.

High-Yield Study Resources and Exam Preparation Strategies

Growing up, I was taught that proper preparation prevents poor performance. This principle holds particularly true when approaching the ABD Certification Pathway. Before diving into high-yield study resources and comprehensive exam preparation strategies, here are some big-picture essentials you need to know:

  • Your residency program covers the fee for the BASIC Exam, but the CORE and APPLIED Exams are out-of-pocket expenses. As of 2026, you should plan to budget $2450 ($200 for 4 CORE module attempts and $2250 for the APPLIED Exam) for all 5 exams.2
  • Testing center space is limited for each test date. While the ABD offers CORE Exams 3 times annually in 2-week windows (Winter [February], Summer [July], and Fall [October/November]), the APPLIED Exam is only given once per year. For the best chance of getting your preferred date, be sure to register as early as possible (especially if you live and train in a city with limited testing sites).
  • After you have successfully passed your first CORE Exam module, you may take up to 3 in one sitting. When taking multiple modules consecutively on the same day, a 15-minute break is configured between each module.

Study Resources

When it comes to studying, there are more resources available than you will have time to explore; therefore, it is crucial to prioritize the ones that best match your learning style. Whether you retain information through visuals, audio, reading comprehension, practice questions, or spaced repetition, there are complimentary and paid high-yield tools designed to support how you learn and make the most of your valuable time outside of clinical responsibilities (Table). Furthermore, there are numerous discipline-specific textbooks and resources encompassing dermatopathology, dermoscopy, trichology, pediatric dermatology, surgical dermatology, cosmetic dermatology, and skin of color.11-13 As a trainee, you also have access to the American Academy of Dermatology’s Learning Center (https://learning.aad.org/Catalogue/AAD-Learning-Center) featuring the Question of the Week series, Board Prep Plus question bank, Dialogues in Dermatology podcast, and continuing medical education articles. Additionally, board review sessions occur at many local, regional, and national dermatology conferences annually.

CT117001020_e-Table_part1CT117001020_e-Table_part2

Exam Preparation Strategy

A comprehensive preparation strategy should begin during your first year of residency and appropriately intensify in the months leading up to the BASIC, CORE, and APPLIED Exams. Ultimately, active learning is ongoing, and your daily clinical work combined with program-sanctioned didactics, journal reading, and conference attendance comprise your framework. I often found it helpful to spend 30 to 60 minutes after clinic each evening reviewing high-yield or interesting cases from the day, as our patients are our greatest teachers. To reinforce key concepts, I used a combination of premade Anki decks14 and custom flashcards for topics that required rote memorization and spaced repetition. Podcasts such as Cutaneous Miscellaneous, The Grenz Zone, and Dermasphere became valuable learning tools that I incorporated into my commutes and long runs. I also enjoyed listening to the Derm In-Review audio study guide.19 Early in residency, I also created a digital notebook on OneNote (https://onenote.cloud.microsoft/en-us/)—organized by postgraduate year and subject—to consolidate notes and procedural pearls. As a fellow, I still use this note-taking system to organize notes from laser and energy-based device trainings and catalogue high-yield conference takeaways. Finally, task management applications can further help you achieve your study goals by organizing assignments, setting deadlines, and breaking larger objectives into manageable steps, making it easier to stay focused and on track.

Test Day Strategies

After sitting for many standardized examinations on the journey to dermatology residency, I am certain that you have cultivated your own reliable test day rituals and strategies; however, if you are looking for additional ones to add to your toolbox, here are a few that helped me stay calm, focused, and in the zone throughout my time in residency.

The Day Before the Test

  • Secure your test-day snacks and preferred form of hydration. I am a fan of cheese sticks for protein and fruit for vitamins and antioxidants. Additionally, I always bring something salty and something sweet (usually chocolate or sour gummy snacks) just in case I happen to get a specific craving on test day.
  • Make sure you have valid forms of identification in accordance with the test center policy.16
  • Confirm your exam location and time. Testing center details can be found on the Pearson Vue portal,16 which is easily accessed via the “ABD Tools” tab on the official ABD website (https://www.abderm.org/). Additionally, the exam location, time, and directions to the test center are located in your Pearson Vue confirmation email.
  • Trust that you are prepared. Try your best to avoid last-minute cramming and prioritize a good night’s sleep.

The Day of the Test

  • Center yourself before the exam. I prefer to start my morning with a run to clear my mind; however, you can also consider other mindfulness exercises such as deep breathing or positive grounding affirmations.
  • Arrive early and dress in layers. You never know if the testing location will run warm or cold.
  • Pace yourself, trust your gut instincts, and do not be afraid to mark and move on if you get stuck on a particular question. Ultimately, make sure you answer every question, as you will not have points deducted for guessing.
  • Make sure to plan something you are excited about for after the exam! That may mean celebrating with co-residents, spending time with loved ones, or just relaxing on the couch and finally catching up on that show you have been meaning to watch for weeks but have not had time for because you have been focused on studying (yes, we all have that one show).

Final Thoughts

While this article is not comprehensive of all ABD Certification Pathway preparation materials and resources, I hope that you will find it helpful along your residency journey. Starting dermatology residency can feel like drinking from a firehose: there is an overwhelming volume of new information, unfamiliar terminology, and a demanding workflow that varies considerably from that of intern year.17 As a resident, it is vital to prioritize your mental health and well-being, as the journey is a marathon rather than a sprint.18

Never forget that you have already come this far; trust in your journey and remember what is meant for you will not miss you. Juggling 6 exams during residency alongside clinical and personal responsibilities is no small feat. With a strong study plan and smart test-day strategies, I have no doubt you will become a board-certified dermatologist!

References
  1. ABD certification pathway info center. Accessed October 1, 2025. https://www.abderm.org/residents-and-fellows/abd-certification-pathway/abd-certification-pathway-info-center
  2. American Board of Dermatology. General exam information. Accessed January 13, 2026. https://www.abderm.org/exams/general-exam-information
  3. James WD, Elston DM, Treat JR, et al, eds. Andrews’ Diseases of the Skin: Clinical Dermatology. 13th ed. Elsevier; 2020.
  4. Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. Elsevier; 2018.
  5. Nelson KC, Cerroni L, Schaffer JV, eds. Dermatology: Comprehensive Board Review and Practice Examinations. 2nd ed. Elsevier; 2019.
  6. Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology Essentials. 2nd ed. Elsevier; 2023.
  7. Saavedra AP, Kang S, Amagai M, et al, eds. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. 9th ed. McGraw Hill; 2023.
  8. Kang S, Amagai M, Bruckner AL, et al, eds. Fitzpatrick’s Dermatology. 9th ed. McGraw Hill; 2019.
  9. Alikhan A, Hocker TL, eds. Review of Dermatology. Elsevier; 2017.
  10. Leventhal JS, Levy LL. Self-Assessment in Dermatology: Questions and Answers. 2nd ed. Elsevier; 2024.
  11. Association of Academic Cosmetic Dermatology. Resources for dermatology residents. Accessed October 15, 2025. https://theaacd.org/resident-resources/
  12. Mukosera GT, Ibraheim MK, Lee MP, et al. From scope to screen: a collection of online dermatopathology resources for residents and fellows. JAAD Int. 2023;12:12-14. doi:10.1016/j.jdin.2022.12.007
  13. Shabeeb N. Dermatology resident education for skin of color. Cutis. 2020;106:E18-E20. doi:10.12788/cutis.0099
  14. Azhar AF. Review of 3 comprehensive Anki flash card decks for dermatology residents. Cutis. 2023;112:E10-E12. doi:10.12788/cutis.0813
  15. ODAC Dermatology. Derm In-Review. Accessed October 22, 2025. https://dermatologyinreview.com/odac/
  16. American Board of Dermatology (ABD) certification testing with Pearson VUE. Accessed October 19, 2025. https://www.pearsonvue.com/us/en/abd.html
  17. Lim YH. Transitioning from an intern to a dermatology resident. Cutis. 2022;110:E14-E16. doi:10.12788/cutis.0638
  18. Lim YH. Prioritizing mental health in residency. Cutis. 2022;109:E36-E38. doi:10.12788/cutis.0551
Article PDF
Author and Disclosure Information

From UnionDerm, New York, New York.

The author has no relevant financial disclosures to report.

Correspondence: Victoria S. Humphrey, MD, UnionDerm, 19 Union Square W, 5th Floor, New York, NY 10003 (victoriashumphrey@gmail.com).

Cutis. 2026 January;117(1):E20-E24. doi:10.12788/cutis.1328

Issue
Cutis - 117(1)
Publications
Topics
Page Number
E20-E24
Sections
Author and Disclosure Information

From UnionDerm, New York, New York.

The author has no relevant financial disclosures to report.

Correspondence: Victoria S. Humphrey, MD, UnionDerm, 19 Union Square W, 5th Floor, New York, NY 10003 (victoriashumphrey@gmail.com).

Cutis. 2026 January;117(1):E20-E24. doi:10.12788/cutis.1328

Author and Disclosure Information

From UnionDerm, New York, New York.

The author has no relevant financial disclosures to report.

Correspondence: Victoria S. Humphrey, MD, UnionDerm, 19 Union Square W, 5th Floor, New York, NY 10003 (victoriashumphrey@gmail.com).

Cutis. 2026 January;117(1):E20-E24. doi:10.12788/cutis.1328

Article PDF
Article PDF

Dermatology trainees are no strangers to standardized examinations that assess basic science and medical knowledge, from the Medical College Admission Test and the National Board of Medical Examiners Subject Examinations to the United States Medical Licensing Examination series (I know, cue the collective flashbacks!). As a dermatology resident, you will complete a series of 6 examinations, culminating with the final APPLIED Exam, which assesses a trainee's ability to apply therapeutic knowledge and clinical reasoning in scenarios relevant to the practice of general dermatology.1 This article features high-yield tips and study resources alongside test-day strategies to help you perform at your best.

The Path to Board Certification for Dermatology Trainees

After years of dedicated study in medical school, navigating the demanding match process, and completing your intern year, you have finally made it to dermatology! With the USMLE Step 3 out of the way, you are now officially able to trade in electrocardiograms for Kodachromes and dermoscopy. As a dermatology trainee, you will complete the American Board of Dermatology (ABD) Certification Pathway—a staged evaluation beginning with a BASIC Exam for first-year residents, which covers dermatology fundamentals and is proctored at your home institution.1 This exam is solely for informational purposes, and ultimately no minimum score is required for certification purposes. Subsequently, second- and third-year residents sit for 4 CORE Exam modules assessing advanced knowledge of the major clinical areas of the specialty: medical dermatology, surgical dermatology, pediatric dermatology, and dermatopathology. These exams consist of 75 to 100 multiple-choice questions per each 2-hour module and are administered either online in a private setting, via a secure online proctoring system, or at an approved testing center. The APPLIED Exam is the final component of the pathway and prioritizes clinical acumen and judgement. This 8-hour, 200-question exam is offered exclusively in person at approved testing centers to residents who have passed all 4 compulsory CORE modules and completed residency training. There is a 20-minute break between sections 1 and 2, a 60-minute break between sections 2 and 3, and a 20-minute break between sections 3 and 4.1 Following successful completion of the ABD Certification Pathway, dermatologists maintain board certification through quarterly CertLink questions, which you must complete at least 3 quarters of each year, and regular completion of focused practice improvement modules every 5 years. Additionally, one must maintain a full and unrestricted medical license in the United States or Canada and pay an annual fee of $150.

High-Yield Study Resources and Exam Preparation Strategies

Growing up, I was taught that proper preparation prevents poor performance. This principle holds particularly true when approaching the ABD Certification Pathway. Before diving into high-yield study resources and comprehensive exam preparation strategies, here are some big-picture essentials you need to know:

  • Your residency program covers the fee for the BASIC Exam, but the CORE and APPLIED Exams are out-of-pocket expenses. As of 2026, you should plan to budget $2450 ($200 for 4 CORE module attempts and $2250 for the APPLIED Exam) for all 5 exams.2
  • Testing center space is limited for each test date. While the ABD offers CORE Exams 3 times annually in 2-week windows (Winter [February], Summer [July], and Fall [October/November]), the APPLIED Exam is only given once per year. For the best chance of getting your preferred date, be sure to register as early as possible (especially if you live and train in a city with limited testing sites).
  • After you have successfully passed your first CORE Exam module, you may take up to 3 in one sitting. When taking multiple modules consecutively on the same day, a 15-minute break is configured between each module.

Study Resources

When it comes to studying, there are more resources available than you will have time to explore; therefore, it is crucial to prioritize the ones that best match your learning style. Whether you retain information through visuals, audio, reading comprehension, practice questions, or spaced repetition, there are complimentary and paid high-yield tools designed to support how you learn and make the most of your valuable time outside of clinical responsibilities (Table). Furthermore, there are numerous discipline-specific textbooks and resources encompassing dermatopathology, dermoscopy, trichology, pediatric dermatology, surgical dermatology, cosmetic dermatology, and skin of color.11-13 As a trainee, you also have access to the American Academy of Dermatology’s Learning Center (https://learning.aad.org/Catalogue/AAD-Learning-Center) featuring the Question of the Week series, Board Prep Plus question bank, Dialogues in Dermatology podcast, and continuing medical education articles. Additionally, board review sessions occur at many local, regional, and national dermatology conferences annually.

CT117001020_e-Table_part1CT117001020_e-Table_part2

Exam Preparation Strategy

A comprehensive preparation strategy should begin during your first year of residency and appropriately intensify in the months leading up to the BASIC, CORE, and APPLIED Exams. Ultimately, active learning is ongoing, and your daily clinical work combined with program-sanctioned didactics, journal reading, and conference attendance comprise your framework. I often found it helpful to spend 30 to 60 minutes after clinic each evening reviewing high-yield or interesting cases from the day, as our patients are our greatest teachers. To reinforce key concepts, I used a combination of premade Anki decks14 and custom flashcards for topics that required rote memorization and spaced repetition. Podcasts such as Cutaneous Miscellaneous, The Grenz Zone, and Dermasphere became valuable learning tools that I incorporated into my commutes and long runs. I also enjoyed listening to the Derm In-Review audio study guide.19 Early in residency, I also created a digital notebook on OneNote (https://onenote.cloud.microsoft/en-us/)—organized by postgraduate year and subject—to consolidate notes and procedural pearls. As a fellow, I still use this note-taking system to organize notes from laser and energy-based device trainings and catalogue high-yield conference takeaways. Finally, task management applications can further help you achieve your study goals by organizing assignments, setting deadlines, and breaking larger objectives into manageable steps, making it easier to stay focused and on track.

Test Day Strategies

After sitting for many standardized examinations on the journey to dermatology residency, I am certain that you have cultivated your own reliable test day rituals and strategies; however, if you are looking for additional ones to add to your toolbox, here are a few that helped me stay calm, focused, and in the zone throughout my time in residency.

The Day Before the Test

  • Secure your test-day snacks and preferred form of hydration. I am a fan of cheese sticks for protein and fruit for vitamins and antioxidants. Additionally, I always bring something salty and something sweet (usually chocolate or sour gummy snacks) just in case I happen to get a specific craving on test day.
  • Make sure you have valid forms of identification in accordance with the test center policy.16
  • Confirm your exam location and time. Testing center details can be found on the Pearson Vue portal,16 which is easily accessed via the “ABD Tools” tab on the official ABD website (https://www.abderm.org/). Additionally, the exam location, time, and directions to the test center are located in your Pearson Vue confirmation email.
  • Trust that you are prepared. Try your best to avoid last-minute cramming and prioritize a good night’s sleep.

The Day of the Test

  • Center yourself before the exam. I prefer to start my morning with a run to clear my mind; however, you can also consider other mindfulness exercises such as deep breathing or positive grounding affirmations.
  • Arrive early and dress in layers. You never know if the testing location will run warm or cold.
  • Pace yourself, trust your gut instincts, and do not be afraid to mark and move on if you get stuck on a particular question. Ultimately, make sure you answer every question, as you will not have points deducted for guessing.
  • Make sure to plan something you are excited about for after the exam! That may mean celebrating with co-residents, spending time with loved ones, or just relaxing on the couch and finally catching up on that show you have been meaning to watch for weeks but have not had time for because you have been focused on studying (yes, we all have that one show).

Final Thoughts

While this article is not comprehensive of all ABD Certification Pathway preparation materials and resources, I hope that you will find it helpful along your residency journey. Starting dermatology residency can feel like drinking from a firehose: there is an overwhelming volume of new information, unfamiliar terminology, and a demanding workflow that varies considerably from that of intern year.17 As a resident, it is vital to prioritize your mental health and well-being, as the journey is a marathon rather than a sprint.18

Never forget that you have already come this far; trust in your journey and remember what is meant for you will not miss you. Juggling 6 exams during residency alongside clinical and personal responsibilities is no small feat. With a strong study plan and smart test-day strategies, I have no doubt you will become a board-certified dermatologist!

Dermatology trainees are no strangers to standardized examinations that assess basic science and medical knowledge, from the Medical College Admission Test and the National Board of Medical Examiners Subject Examinations to the United States Medical Licensing Examination series (I know, cue the collective flashbacks!). As a dermatology resident, you will complete a series of 6 examinations, culminating with the final APPLIED Exam, which assesses a trainee's ability to apply therapeutic knowledge and clinical reasoning in scenarios relevant to the practice of general dermatology.1 This article features high-yield tips and study resources alongside test-day strategies to help you perform at your best.

The Path to Board Certification for Dermatology Trainees

After years of dedicated study in medical school, navigating the demanding match process, and completing your intern year, you have finally made it to dermatology! With the USMLE Step 3 out of the way, you are now officially able to trade in electrocardiograms for Kodachromes and dermoscopy. As a dermatology trainee, you will complete the American Board of Dermatology (ABD) Certification Pathway—a staged evaluation beginning with a BASIC Exam for first-year residents, which covers dermatology fundamentals and is proctored at your home institution.1 This exam is solely for informational purposes, and ultimately no minimum score is required for certification purposes. Subsequently, second- and third-year residents sit for 4 CORE Exam modules assessing advanced knowledge of the major clinical areas of the specialty: medical dermatology, surgical dermatology, pediatric dermatology, and dermatopathology. These exams consist of 75 to 100 multiple-choice questions per each 2-hour module and are administered either online in a private setting, via a secure online proctoring system, or at an approved testing center. The APPLIED Exam is the final component of the pathway and prioritizes clinical acumen and judgement. This 8-hour, 200-question exam is offered exclusively in person at approved testing centers to residents who have passed all 4 compulsory CORE modules and completed residency training. There is a 20-minute break between sections 1 and 2, a 60-minute break between sections 2 and 3, and a 20-minute break between sections 3 and 4.1 Following successful completion of the ABD Certification Pathway, dermatologists maintain board certification through quarterly CertLink questions, which you must complete at least 3 quarters of each year, and regular completion of focused practice improvement modules every 5 years. Additionally, one must maintain a full and unrestricted medical license in the United States or Canada and pay an annual fee of $150.

High-Yield Study Resources and Exam Preparation Strategies

Growing up, I was taught that proper preparation prevents poor performance. This principle holds particularly true when approaching the ABD Certification Pathway. Before diving into high-yield study resources and comprehensive exam preparation strategies, here are some big-picture essentials you need to know:

  • Your residency program covers the fee for the BASIC Exam, but the CORE and APPLIED Exams are out-of-pocket expenses. As of 2026, you should plan to budget $2450 ($200 for 4 CORE module attempts and $2250 for the APPLIED Exam) for all 5 exams.2
  • Testing center space is limited for each test date. While the ABD offers CORE Exams 3 times annually in 2-week windows (Winter [February], Summer [July], and Fall [October/November]), the APPLIED Exam is only given once per year. For the best chance of getting your preferred date, be sure to register as early as possible (especially if you live and train in a city with limited testing sites).
  • After you have successfully passed your first CORE Exam module, you may take up to 3 in one sitting. When taking multiple modules consecutively on the same day, a 15-minute break is configured between each module.

Study Resources

When it comes to studying, there are more resources available than you will have time to explore; therefore, it is crucial to prioritize the ones that best match your learning style. Whether you retain information through visuals, audio, reading comprehension, practice questions, or spaced repetition, there are complimentary and paid high-yield tools designed to support how you learn and make the most of your valuable time outside of clinical responsibilities (Table). Furthermore, there are numerous discipline-specific textbooks and resources encompassing dermatopathology, dermoscopy, trichology, pediatric dermatology, surgical dermatology, cosmetic dermatology, and skin of color.11-13 As a trainee, you also have access to the American Academy of Dermatology’s Learning Center (https://learning.aad.org/Catalogue/AAD-Learning-Center) featuring the Question of the Week series, Board Prep Plus question bank, Dialogues in Dermatology podcast, and continuing medical education articles. Additionally, board review sessions occur at many local, regional, and national dermatology conferences annually.

CT117001020_e-Table_part1CT117001020_e-Table_part2

Exam Preparation Strategy

A comprehensive preparation strategy should begin during your first year of residency and appropriately intensify in the months leading up to the BASIC, CORE, and APPLIED Exams. Ultimately, active learning is ongoing, and your daily clinical work combined with program-sanctioned didactics, journal reading, and conference attendance comprise your framework. I often found it helpful to spend 30 to 60 minutes after clinic each evening reviewing high-yield or interesting cases from the day, as our patients are our greatest teachers. To reinforce key concepts, I used a combination of premade Anki decks14 and custom flashcards for topics that required rote memorization and spaced repetition. Podcasts such as Cutaneous Miscellaneous, The Grenz Zone, and Dermasphere became valuable learning tools that I incorporated into my commutes and long runs. I also enjoyed listening to the Derm In-Review audio study guide.19 Early in residency, I also created a digital notebook on OneNote (https://onenote.cloud.microsoft/en-us/)—organized by postgraduate year and subject—to consolidate notes and procedural pearls. As a fellow, I still use this note-taking system to organize notes from laser and energy-based device trainings and catalogue high-yield conference takeaways. Finally, task management applications can further help you achieve your study goals by organizing assignments, setting deadlines, and breaking larger objectives into manageable steps, making it easier to stay focused and on track.

Test Day Strategies

After sitting for many standardized examinations on the journey to dermatology residency, I am certain that you have cultivated your own reliable test day rituals and strategies; however, if you are looking for additional ones to add to your toolbox, here are a few that helped me stay calm, focused, and in the zone throughout my time in residency.

The Day Before the Test

  • Secure your test-day snacks and preferred form of hydration. I am a fan of cheese sticks for protein and fruit for vitamins and antioxidants. Additionally, I always bring something salty and something sweet (usually chocolate or sour gummy snacks) just in case I happen to get a specific craving on test day.
  • Make sure you have valid forms of identification in accordance with the test center policy.16
  • Confirm your exam location and time. Testing center details can be found on the Pearson Vue portal,16 which is easily accessed via the “ABD Tools” tab on the official ABD website (https://www.abderm.org/). Additionally, the exam location, time, and directions to the test center are located in your Pearson Vue confirmation email.
  • Trust that you are prepared. Try your best to avoid last-minute cramming and prioritize a good night’s sleep.

The Day of the Test

  • Center yourself before the exam. I prefer to start my morning with a run to clear my mind; however, you can also consider other mindfulness exercises such as deep breathing or positive grounding affirmations.
  • Arrive early and dress in layers. You never know if the testing location will run warm or cold.
  • Pace yourself, trust your gut instincts, and do not be afraid to mark and move on if you get stuck on a particular question. Ultimately, make sure you answer every question, as you will not have points deducted for guessing.
  • Make sure to plan something you are excited about for after the exam! That may mean celebrating with co-residents, spending time with loved ones, or just relaxing on the couch and finally catching up on that show you have been meaning to watch for weeks but have not had time for because you have been focused on studying (yes, we all have that one show).

Final Thoughts

While this article is not comprehensive of all ABD Certification Pathway preparation materials and resources, I hope that you will find it helpful along your residency journey. Starting dermatology residency can feel like drinking from a firehose: there is an overwhelming volume of new information, unfamiliar terminology, and a demanding workflow that varies considerably from that of intern year.17 As a resident, it is vital to prioritize your mental health and well-being, as the journey is a marathon rather than a sprint.18

Never forget that you have already come this far; trust in your journey and remember what is meant for you will not miss you. Juggling 6 exams during residency alongside clinical and personal responsibilities is no small feat. With a strong study plan and smart test-day strategies, I have no doubt you will become a board-certified dermatologist!

References
  1. ABD certification pathway info center. Accessed October 1, 2025. https://www.abderm.org/residents-and-fellows/abd-certification-pathway/abd-certification-pathway-info-center
  2. American Board of Dermatology. General exam information. Accessed January 13, 2026. https://www.abderm.org/exams/general-exam-information
  3. James WD, Elston DM, Treat JR, et al, eds. Andrews’ Diseases of the Skin: Clinical Dermatology. 13th ed. Elsevier; 2020.
  4. Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. Elsevier; 2018.
  5. Nelson KC, Cerroni L, Schaffer JV, eds. Dermatology: Comprehensive Board Review and Practice Examinations. 2nd ed. Elsevier; 2019.
  6. Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology Essentials. 2nd ed. Elsevier; 2023.
  7. Saavedra AP, Kang S, Amagai M, et al, eds. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. 9th ed. McGraw Hill; 2023.
  8. Kang S, Amagai M, Bruckner AL, et al, eds. Fitzpatrick’s Dermatology. 9th ed. McGraw Hill; 2019.
  9. Alikhan A, Hocker TL, eds. Review of Dermatology. Elsevier; 2017.
  10. Leventhal JS, Levy LL. Self-Assessment in Dermatology: Questions and Answers. 2nd ed. Elsevier; 2024.
  11. Association of Academic Cosmetic Dermatology. Resources for dermatology residents. Accessed October 15, 2025. https://theaacd.org/resident-resources/
  12. Mukosera GT, Ibraheim MK, Lee MP, et al. From scope to screen: a collection of online dermatopathology resources for residents and fellows. JAAD Int. 2023;12:12-14. doi:10.1016/j.jdin.2022.12.007
  13. Shabeeb N. Dermatology resident education for skin of color. Cutis. 2020;106:E18-E20. doi:10.12788/cutis.0099
  14. Azhar AF. Review of 3 comprehensive Anki flash card decks for dermatology residents. Cutis. 2023;112:E10-E12. doi:10.12788/cutis.0813
  15. ODAC Dermatology. Derm In-Review. Accessed October 22, 2025. https://dermatologyinreview.com/odac/
  16. American Board of Dermatology (ABD) certification testing with Pearson VUE. Accessed October 19, 2025. https://www.pearsonvue.com/us/en/abd.html
  17. Lim YH. Transitioning from an intern to a dermatology resident. Cutis. 2022;110:E14-E16. doi:10.12788/cutis.0638
  18. Lim YH. Prioritizing mental health in residency. Cutis. 2022;109:E36-E38. doi:10.12788/cutis.0551
References
  1. ABD certification pathway info center. Accessed October 1, 2025. https://www.abderm.org/residents-and-fellows/abd-certification-pathway/abd-certification-pathway-info-center
  2. American Board of Dermatology. General exam information. Accessed January 13, 2026. https://www.abderm.org/exams/general-exam-information
  3. James WD, Elston DM, Treat JR, et al, eds. Andrews’ Diseases of the Skin: Clinical Dermatology. 13th ed. Elsevier; 2020.
  4. Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. Elsevier; 2018.
  5. Nelson KC, Cerroni L, Schaffer JV, eds. Dermatology: Comprehensive Board Review and Practice Examinations. 2nd ed. Elsevier; 2019.
  6. Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology Essentials. 2nd ed. Elsevier; 2023.
  7. Saavedra AP, Kang S, Amagai M, et al, eds. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. 9th ed. McGraw Hill; 2023.
  8. Kang S, Amagai M, Bruckner AL, et al, eds. Fitzpatrick’s Dermatology. 9th ed. McGraw Hill; 2019.
  9. Alikhan A, Hocker TL, eds. Review of Dermatology. Elsevier; 2017.
  10. Leventhal JS, Levy LL. Self-Assessment in Dermatology: Questions and Answers. 2nd ed. Elsevier; 2024.
  11. Association of Academic Cosmetic Dermatology. Resources for dermatology residents. Accessed October 15, 2025. https://theaacd.org/resident-resources/
  12. Mukosera GT, Ibraheim MK, Lee MP, et al. From scope to screen: a collection of online dermatopathology resources for residents and fellows. JAAD Int. 2023;12:12-14. doi:10.1016/j.jdin.2022.12.007
  13. Shabeeb N. Dermatology resident education for skin of color. Cutis. 2020;106:E18-E20. doi:10.12788/cutis.0099
  14. Azhar AF. Review of 3 comprehensive Anki flash card decks for dermatology residents. Cutis. 2023;112:E10-E12. doi:10.12788/cutis.0813
  15. ODAC Dermatology. Derm In-Review. Accessed October 22, 2025. https://dermatologyinreview.com/odac/
  16. American Board of Dermatology (ABD) certification testing with Pearson VUE. Accessed October 19, 2025. https://www.pearsonvue.com/us/en/abd.html
  17. Lim YH. Transitioning from an intern to a dermatology resident. Cutis. 2022;110:E14-E16. doi:10.12788/cutis.0638
  18. Lim YH. Prioritizing mental health in residency. Cutis. 2022;109:E36-E38. doi:10.12788/cutis.0551
Issue
Cutis - 117(1)
Issue
Cutis - 117(1)
Page Number
E20-E24
Page Number
E20-E24
Publications
Publications
Topics
Article Type
Display Headline

Dermatology Boards Demystified: Conquer the BASIC, CORE, and APPLIED Exams

Display Headline

Dermatology Boards Demystified: Conquer the BASIC, CORE, and APPLIED Exams

Sections
Inside the Article

Practice Points

  • To become a board-certified dermatologist, one must complete the American Board of Dermatology Certification Pathway—a staged evaluation beginning with a BASIC Exam for first-year residents, followed by 4 CORE Exam modules and a final APPLIED Exam following residency completion.
  • When it comes to studying, there are more resources available than you will have time to explore fully. With so many options available, it is crucial to prioritize the ones that best match your learning style.
  • A comprehensive study strategy begins during your first year of residency and appropriately intensifies in the months leading up to the exams. Make sure to cultivate test day strategies to help you stay calm, focused, and in the zone.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Treatment of Acne Keloidalis Nuchae in a Southern California Population

Article Type
Changed
Display Headline

Treatment of Acne Keloidalis Nuchae in a Southern California Population

Acne keloidalis nuchae (AKN) classically presents as chronic inflammation of the hair follicles on the occipital scalp/nape of the neck manifesting as papules and pustules that may progress to keloidlike scarring.1 Photographs depicting the typical clinical presentation of AKN are shown in the Figure. In the literature, AKN has been described as primarily occurring in postpubertal males of African descent.2 Despite its similar name, AKN is not related to acne vulgaris.3 The underlying cause of AKN is hypothesized to be multifactorial, including inflammation, infection, and trauma.2 Acne keloidalis nuchae is most common in males aged 14 to 50 years, which may indicate that increased androgens contribute to its development.3 In some cases, patients have reported developing AKN lesions after receiving a haircut or shaving, suggesting a potential role of trauma to the hair follicles and secondary infection.2 Histopathology typically shows a perifollicular inflammatory infiltrate that obscures the hair follicles with associated proximal fibrosis.4 On physical examination, dermoscopy can be used to visualize perifollicular pustules and fibrosis, which appears white, in the early stages of AKN. Patients may present with tufted hairs in more advanced stages.5 Patients with AKN often describe the lesions as pruritic and painful.2

CT117002060-ABC
FIGURE. Typical clinical manifestations of acne keloidalis nuchae. A, Flesh-colored papules on the occipital scalp, with a patch of nonscarring hair loss in the left upper portion of the affected area. B, Erythematous perifollicular papules and pustules with overlying crusting on the posterior scalp. Keloidlike plaques composed of coalescing fibrotic papules are visualized at the medial portion of the posterior hairline, the left posterior hairline, and the right posterior scalp at the level of the auricle. C, Numerous erythematous and flesh-colored papules of varying sizes with surrounding background erythema on the occipital scalp and posterior neck.

In this study, we evaluated the most common treatment regimens used over a 6-year period by patients in the Los Angeles County hospital system in California and their efficacy on AKN lesions. Our study includes one of the largest cohorts of patients reported to date and as such demonstrates the real-world effects that current treatment regimens for AKN have on patient outcomes nationwide.

Methods

We performed a retrospective cross-sectional analysis of patient medical records from the Los Angeles County hospital system i2b2 (i2b2 tranSMART Foundation) clinical data warehouse over a 6-year period (January 2017–January 2023). We used the International Statistical Classification of Diseases, Tenth Revision codes L73.0 (acne keloid) and L73.1 (pseudofolliculitis barbae) to conduct our search in order to identify as many patients with follicular disorders as possible to include in the study. Of the 478 total medical records we reviewed, 183 patients were included based on a diagnosis of AKN by a dermatologist.

We then collected data on patient demographics and treatments received, including whether patients had received monotherapy or combination therapy. Of the 183 patients we initially identified, 4 were excluded from the study because they had not received any treatment, and 78 were excluded because no treatment outcomes were documented. The 101 patients who were included had received either monotherapy or a combination of treatments. Treatment outcomes were categorized as either improvement in the number and appearance of papules and/or keloidlike plaques, maintenance of stable lesions (ie, well controlled), and/or resolution of lesions as documented by the treating physician. No patients had overall worsening of their disease.

Results

Of the 101 patients included in the study, 34 (33.7%) received a combination of topical, systemic, and procedural treatments; 34 (33.7%) received a combination of topical and procedural treatments; 17 (16.8%) were treated with topicals only; 13 (12.9%) were treated with a combination of topical and systemic treatments; and 3 (3.0%) were treated with monotherapy of either a topical, systemic, or procedural therapy. Systemic and/or procedural therapy combined with topicals was provided as a first-line treatment for 63 (62.4%) patients. Treatment escalation to systemic or procedural therapy for those who did not respond to topical treatment was observed in 23 (22.8%) patients. The average number of unique treatments received per patient was 3.67.

Clindamycin and clobetasol were the most prescribed topical treatments, doxycycline was the most prescribed systemic therapy, and intralesional (IL) triamcinolone was the most performed procedural therapy. The most common treatment regimens were topical clindamycin and clobetasol, topical clindamycin and clobetasol with IL triamcinolone, and topical clindamycin and clobetasol with both IL triamcinolone and doxycycline.

Improvement in AKN lesions was reported for the majority of patients with known treatment outcomes across all types of regimens. Ninety-eight percent (99/101) of patients had improvement in lesions, 55.5% (56/101) had well-controlled lesions, and 20.8% (21/101) achieved resolution of disease. The treatment outcomes are outlined in eTables 1 and 2.

CT117002060-eTable1CT117002060-eTable2_part1CT117002060-eTable2_part2

Comment

Most clinicians opted for a multitherapy treatment regimen, and improvement was noted in most patients regardless of which regimen was chosen. As expected, patients who had mild or early disease generally received topical agents first, including most commonly a mid- to high-potency steroid, antibiotic, retinoid, and/or antifungal; specifically, clindamycin, clobetasol, and fluocinolone were the most common agents chosen. Patients with severe disease were more likely to receive systemic and/or procedural treatments, including oral antibiotics or IL steroid injections most commonly. Improvement was documented in the majority of patients using these treatment regimens, and some patients did achieve full resolution of disease.

Our data cannot be used to determine which treatment alone is most effective for patients with AKN, as the patients in our study had varying levels of disease activity and types of lesions, and most received combination therapy. What our data do show is that combination therapies often work well to control or improve disease, but also that current therapeutic options only rarely lead to full resolution of disease.

Limitations of our study included an inability to stratify disease, an inability to rigorously analyze specific treatment outcomes since most patients did not receive monotherapy. The strength of our study is its size, which allows us to show that many different treatment regimens currently are being employed by dermatologists to treat AKN, and most of these seem to be somewhat effective.

Conclusion

Acne keloidalis nuchae is difficult to treat due to a lack of understanding of which pathophysiologic mechanisms dominate in any given patient, a lack of good data on treatment outcomes, and the variability of ways that the disease manifests. Thus far, as shown by the patients described in this study, the most efficacious treatment regimens seem to be combination therapies that target the multifactorial causes of this disease. Physicians should continue to choose treatments based on disease severity and cutaneous manifestations, tailor their approach by accounting for patient preferences, and consider a multimodal approach to treatment.

References
  1. Maranda EL, Simmons BJ, Nguyen AH, et al. Treatment of acne keloidalis nuchae: a systematic review of the literature. Dermatol Ther. 2016;6:363-378. doi:10.1007/s13555-016-0134-5<
  2. Ogunbiyi A, Adedokun B. Perceived aetiological factors of folliculitis keloidalis nuchae (acne keloidalis) and treatment options among Nigerian men. Br J Dermatol. 2015;173(Suppl 2):22-25. doi:10.1111/bjd.13422
  3. East-Innis ADC, Stylianou K, Paolino A, et al. Acne keloidalis nuchae: risk factors and associated disorders – a retrospective study. Int J Dermatol. 2017;56:828-832. doi:10.1111/ijd.13678
  4. Goette DK, Berger TG. Acne keloidalis nuchae. A transepithelial elimination disorder. Int J Dermatol. 1987;26:442-444. doi:10.1111/j.1365-4362.1987.tb00587.x
  5. Chouk C, Litaiem N, Jones M, et al. Acne keloidalis nuchae: clinical and dermoscopic features. BMJ Case Rep. 2017;2017:bcr2017222222. doi:10.1136/bcr-2017-222222
Article PDF
Author and Disclosure Information

From the Keck School of Medicine, University of Southern California, Los Angeles. Dr. Worswick is from the Department of Dermatology. 

Kimberly Smart and Dr. Rodriguez have no relevant financial disclosures to report. Dr. Worswick is a speaker for Boehringer Ingelheim.

The University of Southern California Institutional Review Board reviewed this study and determined that it qualified as exempt 8 under the USC Human Research Protection Program Flexibility Policy and issued approval HS-18-00640.

Correspondence: Kimberly Smart, BS, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, Ezralow Tower, Ste 5301, Los Angeles, CA 90033 (ksmart@usc.edu).

Cutis. 2026 February;117(2):60-61, 64, E1-E3. doi:10.12788/cutis.1332

Issue
Cutis - 117(2)
Publications
Topics
Page Number
60-61, 64
Sections
Author and Disclosure Information

From the Keck School of Medicine, University of Southern California, Los Angeles. Dr. Worswick is from the Department of Dermatology. 

Kimberly Smart and Dr. Rodriguez have no relevant financial disclosures to report. Dr. Worswick is a speaker for Boehringer Ingelheim.

The University of Southern California Institutional Review Board reviewed this study and determined that it qualified as exempt 8 under the USC Human Research Protection Program Flexibility Policy and issued approval HS-18-00640.

Correspondence: Kimberly Smart, BS, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, Ezralow Tower, Ste 5301, Los Angeles, CA 90033 (ksmart@usc.edu).

Cutis. 2026 February;117(2):60-61, 64, E1-E3. doi:10.12788/cutis.1332

Author and Disclosure Information

From the Keck School of Medicine, University of Southern California, Los Angeles. Dr. Worswick is from the Department of Dermatology. 

Kimberly Smart and Dr. Rodriguez have no relevant financial disclosures to report. Dr. Worswick is a speaker for Boehringer Ingelheim.

The University of Southern California Institutional Review Board reviewed this study and determined that it qualified as exempt 8 under the USC Human Research Protection Program Flexibility Policy and issued approval HS-18-00640.

Correspondence: Kimberly Smart, BS, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, Ezralow Tower, Ste 5301, Los Angeles, CA 90033 (ksmart@usc.edu).

Cutis. 2026 February;117(2):60-61, 64, E1-E3. doi:10.12788/cutis.1332

Article PDF
Article PDF

Acne keloidalis nuchae (AKN) classically presents as chronic inflammation of the hair follicles on the occipital scalp/nape of the neck manifesting as papules and pustules that may progress to keloidlike scarring.1 Photographs depicting the typical clinical presentation of AKN are shown in the Figure. In the literature, AKN has been described as primarily occurring in postpubertal males of African descent.2 Despite its similar name, AKN is not related to acne vulgaris.3 The underlying cause of AKN is hypothesized to be multifactorial, including inflammation, infection, and trauma.2 Acne keloidalis nuchae is most common in males aged 14 to 50 years, which may indicate that increased androgens contribute to its development.3 In some cases, patients have reported developing AKN lesions after receiving a haircut or shaving, suggesting a potential role of trauma to the hair follicles and secondary infection.2 Histopathology typically shows a perifollicular inflammatory infiltrate that obscures the hair follicles with associated proximal fibrosis.4 On physical examination, dermoscopy can be used to visualize perifollicular pustules and fibrosis, which appears white, in the early stages of AKN. Patients may present with tufted hairs in more advanced stages.5 Patients with AKN often describe the lesions as pruritic and painful.2

CT117002060-ABC
FIGURE. Typical clinical manifestations of acne keloidalis nuchae. A, Flesh-colored papules on the occipital scalp, with a patch of nonscarring hair loss in the left upper portion of the affected area. B, Erythematous perifollicular papules and pustules with overlying crusting on the posterior scalp. Keloidlike plaques composed of coalescing fibrotic papules are visualized at the medial portion of the posterior hairline, the left posterior hairline, and the right posterior scalp at the level of the auricle. C, Numerous erythematous and flesh-colored papules of varying sizes with surrounding background erythema on the occipital scalp and posterior neck.

In this study, we evaluated the most common treatment regimens used over a 6-year period by patients in the Los Angeles County hospital system in California and their efficacy on AKN lesions. Our study includes one of the largest cohorts of patients reported to date and as such demonstrates the real-world effects that current treatment regimens for AKN have on patient outcomes nationwide.

Methods

We performed a retrospective cross-sectional analysis of patient medical records from the Los Angeles County hospital system i2b2 (i2b2 tranSMART Foundation) clinical data warehouse over a 6-year period (January 2017–January 2023). We used the International Statistical Classification of Diseases, Tenth Revision codes L73.0 (acne keloid) and L73.1 (pseudofolliculitis barbae) to conduct our search in order to identify as many patients with follicular disorders as possible to include in the study. Of the 478 total medical records we reviewed, 183 patients were included based on a diagnosis of AKN by a dermatologist.

We then collected data on patient demographics and treatments received, including whether patients had received monotherapy or combination therapy. Of the 183 patients we initially identified, 4 were excluded from the study because they had not received any treatment, and 78 were excluded because no treatment outcomes were documented. The 101 patients who were included had received either monotherapy or a combination of treatments. Treatment outcomes were categorized as either improvement in the number and appearance of papules and/or keloidlike plaques, maintenance of stable lesions (ie, well controlled), and/or resolution of lesions as documented by the treating physician. No patients had overall worsening of their disease.

Results

Of the 101 patients included in the study, 34 (33.7%) received a combination of topical, systemic, and procedural treatments; 34 (33.7%) received a combination of topical and procedural treatments; 17 (16.8%) were treated with topicals only; 13 (12.9%) were treated with a combination of topical and systemic treatments; and 3 (3.0%) were treated with monotherapy of either a topical, systemic, or procedural therapy. Systemic and/or procedural therapy combined with topicals was provided as a first-line treatment for 63 (62.4%) patients. Treatment escalation to systemic or procedural therapy for those who did not respond to topical treatment was observed in 23 (22.8%) patients. The average number of unique treatments received per patient was 3.67.

Clindamycin and clobetasol were the most prescribed topical treatments, doxycycline was the most prescribed systemic therapy, and intralesional (IL) triamcinolone was the most performed procedural therapy. The most common treatment regimens were topical clindamycin and clobetasol, topical clindamycin and clobetasol with IL triamcinolone, and topical clindamycin and clobetasol with both IL triamcinolone and doxycycline.

Improvement in AKN lesions was reported for the majority of patients with known treatment outcomes across all types of regimens. Ninety-eight percent (99/101) of patients had improvement in lesions, 55.5% (56/101) had well-controlled lesions, and 20.8% (21/101) achieved resolution of disease. The treatment outcomes are outlined in eTables 1 and 2.

CT117002060-eTable1CT117002060-eTable2_part1CT117002060-eTable2_part2

Comment

Most clinicians opted for a multitherapy treatment regimen, and improvement was noted in most patients regardless of which regimen was chosen. As expected, patients who had mild or early disease generally received topical agents first, including most commonly a mid- to high-potency steroid, antibiotic, retinoid, and/or antifungal; specifically, clindamycin, clobetasol, and fluocinolone were the most common agents chosen. Patients with severe disease were more likely to receive systemic and/or procedural treatments, including oral antibiotics or IL steroid injections most commonly. Improvement was documented in the majority of patients using these treatment regimens, and some patients did achieve full resolution of disease.

Our data cannot be used to determine which treatment alone is most effective for patients with AKN, as the patients in our study had varying levels of disease activity and types of lesions, and most received combination therapy. What our data do show is that combination therapies often work well to control or improve disease, but also that current therapeutic options only rarely lead to full resolution of disease.

Limitations of our study included an inability to stratify disease, an inability to rigorously analyze specific treatment outcomes since most patients did not receive monotherapy. The strength of our study is its size, which allows us to show that many different treatment regimens currently are being employed by dermatologists to treat AKN, and most of these seem to be somewhat effective.

Conclusion

Acne keloidalis nuchae is difficult to treat due to a lack of understanding of which pathophysiologic mechanisms dominate in any given patient, a lack of good data on treatment outcomes, and the variability of ways that the disease manifests. Thus far, as shown by the patients described in this study, the most efficacious treatment regimens seem to be combination therapies that target the multifactorial causes of this disease. Physicians should continue to choose treatments based on disease severity and cutaneous manifestations, tailor their approach by accounting for patient preferences, and consider a multimodal approach to treatment.

Acne keloidalis nuchae (AKN) classically presents as chronic inflammation of the hair follicles on the occipital scalp/nape of the neck manifesting as papules and pustules that may progress to keloidlike scarring.1 Photographs depicting the typical clinical presentation of AKN are shown in the Figure. In the literature, AKN has been described as primarily occurring in postpubertal males of African descent.2 Despite its similar name, AKN is not related to acne vulgaris.3 The underlying cause of AKN is hypothesized to be multifactorial, including inflammation, infection, and trauma.2 Acne keloidalis nuchae is most common in males aged 14 to 50 years, which may indicate that increased androgens contribute to its development.3 In some cases, patients have reported developing AKN lesions after receiving a haircut or shaving, suggesting a potential role of trauma to the hair follicles and secondary infection.2 Histopathology typically shows a perifollicular inflammatory infiltrate that obscures the hair follicles with associated proximal fibrosis.4 On physical examination, dermoscopy can be used to visualize perifollicular pustules and fibrosis, which appears white, in the early stages of AKN. Patients may present with tufted hairs in more advanced stages.5 Patients with AKN often describe the lesions as pruritic and painful.2

CT117002060-ABC
FIGURE. Typical clinical manifestations of acne keloidalis nuchae. A, Flesh-colored papules on the occipital scalp, with a patch of nonscarring hair loss in the left upper portion of the affected area. B, Erythematous perifollicular papules and pustules with overlying crusting on the posterior scalp. Keloidlike plaques composed of coalescing fibrotic papules are visualized at the medial portion of the posterior hairline, the left posterior hairline, and the right posterior scalp at the level of the auricle. C, Numerous erythematous and flesh-colored papules of varying sizes with surrounding background erythema on the occipital scalp and posterior neck.

In this study, we evaluated the most common treatment regimens used over a 6-year period by patients in the Los Angeles County hospital system in California and their efficacy on AKN lesions. Our study includes one of the largest cohorts of patients reported to date and as such demonstrates the real-world effects that current treatment regimens for AKN have on patient outcomes nationwide.

Methods

We performed a retrospective cross-sectional analysis of patient medical records from the Los Angeles County hospital system i2b2 (i2b2 tranSMART Foundation) clinical data warehouse over a 6-year period (January 2017–January 2023). We used the International Statistical Classification of Diseases, Tenth Revision codes L73.0 (acne keloid) and L73.1 (pseudofolliculitis barbae) to conduct our search in order to identify as many patients with follicular disorders as possible to include in the study. Of the 478 total medical records we reviewed, 183 patients were included based on a diagnosis of AKN by a dermatologist.

We then collected data on patient demographics and treatments received, including whether patients had received monotherapy or combination therapy. Of the 183 patients we initially identified, 4 were excluded from the study because they had not received any treatment, and 78 were excluded because no treatment outcomes were documented. The 101 patients who were included had received either monotherapy or a combination of treatments. Treatment outcomes were categorized as either improvement in the number and appearance of papules and/or keloidlike plaques, maintenance of stable lesions (ie, well controlled), and/or resolution of lesions as documented by the treating physician. No patients had overall worsening of their disease.

Results

Of the 101 patients included in the study, 34 (33.7%) received a combination of topical, systemic, and procedural treatments; 34 (33.7%) received a combination of topical and procedural treatments; 17 (16.8%) were treated with topicals only; 13 (12.9%) were treated with a combination of topical and systemic treatments; and 3 (3.0%) were treated with monotherapy of either a topical, systemic, or procedural therapy. Systemic and/or procedural therapy combined with topicals was provided as a first-line treatment for 63 (62.4%) patients. Treatment escalation to systemic or procedural therapy for those who did not respond to topical treatment was observed in 23 (22.8%) patients. The average number of unique treatments received per patient was 3.67.

Clindamycin and clobetasol were the most prescribed topical treatments, doxycycline was the most prescribed systemic therapy, and intralesional (IL) triamcinolone was the most performed procedural therapy. The most common treatment regimens were topical clindamycin and clobetasol, topical clindamycin and clobetasol with IL triamcinolone, and topical clindamycin and clobetasol with both IL triamcinolone and doxycycline.

Improvement in AKN lesions was reported for the majority of patients with known treatment outcomes across all types of regimens. Ninety-eight percent (99/101) of patients had improvement in lesions, 55.5% (56/101) had well-controlled lesions, and 20.8% (21/101) achieved resolution of disease. The treatment outcomes are outlined in eTables 1 and 2.

CT117002060-eTable1CT117002060-eTable2_part1CT117002060-eTable2_part2

Comment

Most clinicians opted for a multitherapy treatment regimen, and improvement was noted in most patients regardless of which regimen was chosen. As expected, patients who had mild or early disease generally received topical agents first, including most commonly a mid- to high-potency steroid, antibiotic, retinoid, and/or antifungal; specifically, clindamycin, clobetasol, and fluocinolone were the most common agents chosen. Patients with severe disease were more likely to receive systemic and/or procedural treatments, including oral antibiotics or IL steroid injections most commonly. Improvement was documented in the majority of patients using these treatment regimens, and some patients did achieve full resolution of disease.

Our data cannot be used to determine which treatment alone is most effective for patients with AKN, as the patients in our study had varying levels of disease activity and types of lesions, and most received combination therapy. What our data do show is that combination therapies often work well to control or improve disease, but also that current therapeutic options only rarely lead to full resolution of disease.

Limitations of our study included an inability to stratify disease, an inability to rigorously analyze specific treatment outcomes since most patients did not receive monotherapy. The strength of our study is its size, which allows us to show that many different treatment regimens currently are being employed by dermatologists to treat AKN, and most of these seem to be somewhat effective.

Conclusion

Acne keloidalis nuchae is difficult to treat due to a lack of understanding of which pathophysiologic mechanisms dominate in any given patient, a lack of good data on treatment outcomes, and the variability of ways that the disease manifests. Thus far, as shown by the patients described in this study, the most efficacious treatment regimens seem to be combination therapies that target the multifactorial causes of this disease. Physicians should continue to choose treatments based on disease severity and cutaneous manifestations, tailor their approach by accounting for patient preferences, and consider a multimodal approach to treatment.

References
  1. Maranda EL, Simmons BJ, Nguyen AH, et al. Treatment of acne keloidalis nuchae: a systematic review of the literature. Dermatol Ther. 2016;6:363-378. doi:10.1007/s13555-016-0134-5<
  2. Ogunbiyi A, Adedokun B. Perceived aetiological factors of folliculitis keloidalis nuchae (acne keloidalis) and treatment options among Nigerian men. Br J Dermatol. 2015;173(Suppl 2):22-25. doi:10.1111/bjd.13422
  3. East-Innis ADC, Stylianou K, Paolino A, et al. Acne keloidalis nuchae: risk factors and associated disorders – a retrospective study. Int J Dermatol. 2017;56:828-832. doi:10.1111/ijd.13678
  4. Goette DK, Berger TG. Acne keloidalis nuchae. A transepithelial elimination disorder. Int J Dermatol. 1987;26:442-444. doi:10.1111/j.1365-4362.1987.tb00587.x
  5. Chouk C, Litaiem N, Jones M, et al. Acne keloidalis nuchae: clinical and dermoscopic features. BMJ Case Rep. 2017;2017:bcr2017222222. doi:10.1136/bcr-2017-222222
References
  1. Maranda EL, Simmons BJ, Nguyen AH, et al. Treatment of acne keloidalis nuchae: a systematic review of the literature. Dermatol Ther. 2016;6:363-378. doi:10.1007/s13555-016-0134-5<
  2. Ogunbiyi A, Adedokun B. Perceived aetiological factors of folliculitis keloidalis nuchae (acne keloidalis) and treatment options among Nigerian men. Br J Dermatol. 2015;173(Suppl 2):22-25. doi:10.1111/bjd.13422
  3. East-Innis ADC, Stylianou K, Paolino A, et al. Acne keloidalis nuchae: risk factors and associated disorders – a retrospective study. Int J Dermatol. 2017;56:828-832. doi:10.1111/ijd.13678
  4. Goette DK, Berger TG. Acne keloidalis nuchae. A transepithelial elimination disorder. Int J Dermatol. 1987;26:442-444. doi:10.1111/j.1365-4362.1987.tb00587.x
  5. Chouk C, Litaiem N, Jones M, et al. Acne keloidalis nuchae: clinical and dermoscopic features. BMJ Case Rep. 2017;2017:bcr2017222222. doi:10.1136/bcr-2017-222222
Issue
Cutis - 117(2)
Issue
Cutis - 117(2)
Page Number
60-61, 64
Page Number
60-61, 64
Publications
Publications
Topics
Article Type
Display Headline

Treatment of Acne Keloidalis Nuchae in a Southern California Population

Display Headline

Treatment of Acne Keloidalis Nuchae in a Southern California Population

Sections
Inside the Article

PRACTICE POINTS

  • Acne keloidalis nuchae (AKN) is a rare inflammatory skin disease that manifests with papules, pustules, and plaques on the occipital scalp.
  • Initial treatment for patients with mild to moderate AKN disease most commonly is topical clindamycin and clobetasol; patients with moderate to severe AKN disease may require adjunctive treatment with oral doxycycline and/or intralesional triamcinolone.
  • Combination therapy that targets the multifactorial pathophysiology of AKN (inflammatory, infectious, and traumatic) is most efficacious overall.
  • The majority of patients experience improvement of AKN with treatment, but full resolution is less common.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Impact of a Museum-Based Retreat on the Clinical Skills and Well-Being of Dermatology Residents and Faculty

Article Type
Changed
Display Headline

Impact of a Museum-Based Retreat on the Clinical Skills and Well-Being of Dermatology Residents and Faculty

IN PARTNERSHIP WITH THE ASSOCIATION OF PROFESSORS OF DERMATOLOGY RESIDENCY PROGRAM DIRECTORS SECTION

Prior research has demonstrated that museum-based programming decreases resident burnout and depersonalization.1 A partnership between the Museum of Fine Arts Boston and the Harvard Combined Dermatology Residency Program was well received by residents and resulted in improvement of their observational skills.2 The impact of museum-based programming on the clinical practice skills and well-being of Duke dermatology residents and faculty has not been previously assessed.

In this study, our objective was to evaluate the impact of a 3-part museum-based arts retreat on arts appreciation, clinical practice skills, and well-being among dermatology resident and faculty participants. Surveys administered before and after the retreat were used to assess the value that participants attributed to the arts in various areas of clinical practice.

Methods

A 3-part museum-based retreat held on February 7, 2024, was developed with a Nasher Museum of Art (Durham, North Carolina) curator (E.R.). Part 1 was a personal response tour in which 15 residents and 3 faculty members were given individualized prompts and asked to identify an art piece in the museum that encapsulated their response; they then were asked to explain to the group why they chose that particular piece. Participants were given 10 minutes to explore the museum galleries to choose their piece, followed by 15 minutes to share their selected work in groups of 3 to 4.

Part 2 encompassed visual-thinking strategies, a research-based method that uses art to teach visual literacy, thinking, and communication skills.2 Using this method, facilitators follow a specific protocol to guide participants in the exploration of an art piece through sharing observations and interpretations.4 Participants were divided into 2 groups led by trained museum educators (including E.R.) to analyze and ascribe meaning to a chosen art piece. Three questions were asked: What’s going on in this picture? What do you see that makes you say that? What else can we find? 

Part 3 involved back-to-back drawing, in which participants were paired up and tasked with recreating an art piece in the museum based solely on their partner’s verbal description. In each pair, both participants took turns as the describer and the drawer.

After each part of the retreat, 5 to 10 minutes were dedicated to debriefing in small groups about how each activity may connect to the role of a clinician. A total of 15 participants completed pre- and post-retreat surveys to assess the value they attributed to the arts and identify in which aspects of clinical practice they believe the arts play a role.

Results

Seventy-three percent of participants (11/15) found the museum-based retreat “extremely useful” or “very useful.” There was a 20% increase in those who attributed at least moderate value to the arts as a clinician after compared to before the retreat (13/15 [87%] vs 8/15 [53%]), and 100% of the participants desired to participate in future arts-based programming. Following the retreat, a greater percentage of participants believed the arts have a role in the following aspects of clinical practice: education, observation, listening, communication, empathy, compassion, forming connections, cultural sensitivity, tolerance for ambiguity, reflection, mindfulness, stress reduction, preventing burnout, bias prevention, mental wellness, spiritual wellness, and physical wellness (eTable). Qualitative feedback compiled from the participants’ responses to survey questions following the retreat about their thoughts on each activity and overall feedback was used to create a word cloud (eFigure).

Guo eTable
Guo eFig
eFIGURE. Word cloud depicting qualitative feedback compiled from participants’ post-retreat survey responses.

Comment

The importance of arts and humanities integration into medical education previously has been described.5 Our survey results suggest that museum-based programming increases dermatology resident and faculty appreciation for the arts and encourages participation in future arts-based programming. Our results also demonstrate that arts-based programming positively impacts important resident competencies in the practice of medicine including tolerance for ambiguity, bias prevention, and cultural competency, and that the incorporation of arts-based programming can enhance residents’ well-being (physical, mental, and spiritual) as well as their ability to be better clinicians by addressing skills in communication, listening, and observation. The structure of our 3-part museum-based retreat offers practical implementation strategies for integrating the humanities into dermatology residency curricula and easily can be modified to meet the needs of different dermatology residency programs. 

References
  1. Orr AR, Moghbeli N, Swain A, et al. The Fostering Resilience through Art in Medical Education (FRAME) workshop: a partnership with the Philadelphia Museum of Art. Adv Med Educ Pract. 2019;10:361-369. doi:10.2147/AMEP.S194575

  2. Zimmermann C, Huang JT, Buzney EA. Refining the eye: dermatology and visual literacy. J Museum Ed. 2016;41:116-122.

  3. Yenawine P. Visual Thinking Strategies: Using Art to Deepen Learning Across School Disciplines. Harvard Education Press; 2013.

  4. Hailey D, Miller A, Yenawine P. Understanding visual literacy: the visual thinking strategies approach. In: Baylen DM, D’Alba A. Essentials of Teaching and Integrating Visual and Media Literacy: Visualizing Learning. Springer Cham; 2015:49-73. doi:10.1007/978-3-319-05837-5

  5. Howley L, Gaufberg E, King BE. The Fundamental Role of the Arts and Humanities in Medical Education. Association of American Medical Colleges; 2020. Accessed December 18, 2025. https://store.aamc.org/the-fundamental-role-of-the-arts-and-humanities-in-medical-education.html

Article PDF
Author and Disclosure Information

From Duke University, Chapel Hill, North Carolina. Robyn Guo Ku is from the School of Medicine, Drs. Fresco and Lesesky are from the Department of Dermatology, and Dr. Raimond is from the Nasher Museum of Art. 

The authors have no relevant financial disclosures to report. 

The eTable and eFigure are available in the Appendix online at www.mdedge.com/cutis. 

Correspondence: Erin Lesesky, MD, Duke University Medical Center, Department of Dermatology, DUMC 3135, Durham, NC 27710 (erin.lesesky@duke.edu). 

Cutis. 2026 January;117(1):10,15, E7-E8. doi:10.12788/cutis.1320

Issue
Cutis - 117(1)
Publications
Topics
Page Number
10,15, E7-E8
Sections
Author and Disclosure Information

From Duke University, Chapel Hill, North Carolina. Robyn Guo Ku is from the School of Medicine, Drs. Fresco and Lesesky are from the Department of Dermatology, and Dr. Raimond is from the Nasher Museum of Art. 

The authors have no relevant financial disclosures to report. 

The eTable and eFigure are available in the Appendix online at www.mdedge.com/cutis. 

Correspondence: Erin Lesesky, MD, Duke University Medical Center, Department of Dermatology, DUMC 3135, Durham, NC 27710 (erin.lesesky@duke.edu). 

Cutis. 2026 January;117(1):10,15, E7-E8. doi:10.12788/cutis.1320

Author and Disclosure Information

From Duke University, Chapel Hill, North Carolina. Robyn Guo Ku is from the School of Medicine, Drs. Fresco and Lesesky are from the Department of Dermatology, and Dr. Raimond is from the Nasher Museum of Art. 

The authors have no relevant financial disclosures to report. 

The eTable and eFigure are available in the Appendix online at www.mdedge.com/cutis. 

Correspondence: Erin Lesesky, MD, Duke University Medical Center, Department of Dermatology, DUMC 3135, Durham, NC 27710 (erin.lesesky@duke.edu). 

Cutis. 2026 January;117(1):10,15, E7-E8. doi:10.12788/cutis.1320

Article PDF
Article PDF
IN PARTNERSHIP WITH THE ASSOCIATION OF PROFESSORS OF DERMATOLOGY RESIDENCY PROGRAM DIRECTORS SECTION
IN PARTNERSHIP WITH THE ASSOCIATION OF PROFESSORS OF DERMATOLOGY RESIDENCY PROGRAM DIRECTORS SECTION

Prior research has demonstrated that museum-based programming decreases resident burnout and depersonalization.1 A partnership between the Museum of Fine Arts Boston and the Harvard Combined Dermatology Residency Program was well received by residents and resulted in improvement of their observational skills.2 The impact of museum-based programming on the clinical practice skills and well-being of Duke dermatology residents and faculty has not been previously assessed.

In this study, our objective was to evaluate the impact of a 3-part museum-based arts retreat on arts appreciation, clinical practice skills, and well-being among dermatology resident and faculty participants. Surveys administered before and after the retreat were used to assess the value that participants attributed to the arts in various areas of clinical practice.

Methods

A 3-part museum-based retreat held on February 7, 2024, was developed with a Nasher Museum of Art (Durham, North Carolina) curator (E.R.). Part 1 was a personal response tour in which 15 residents and 3 faculty members were given individualized prompts and asked to identify an art piece in the museum that encapsulated their response; they then were asked to explain to the group why they chose that particular piece. Participants were given 10 minutes to explore the museum galleries to choose their piece, followed by 15 minutes to share their selected work in groups of 3 to 4.

Part 2 encompassed visual-thinking strategies, a research-based method that uses art to teach visual literacy, thinking, and communication skills.2 Using this method, facilitators follow a specific protocol to guide participants in the exploration of an art piece through sharing observations and interpretations.4 Participants were divided into 2 groups led by trained museum educators (including E.R.) to analyze and ascribe meaning to a chosen art piece. Three questions were asked: What’s going on in this picture? What do you see that makes you say that? What else can we find? 

Part 3 involved back-to-back drawing, in which participants were paired up and tasked with recreating an art piece in the museum based solely on their partner’s verbal description. In each pair, both participants took turns as the describer and the drawer.

After each part of the retreat, 5 to 10 minutes were dedicated to debriefing in small groups about how each activity may connect to the role of a clinician. A total of 15 participants completed pre- and post-retreat surveys to assess the value they attributed to the arts and identify in which aspects of clinical practice they believe the arts play a role.

Results

Seventy-three percent of participants (11/15) found the museum-based retreat “extremely useful” or “very useful.” There was a 20% increase in those who attributed at least moderate value to the arts as a clinician after compared to before the retreat (13/15 [87%] vs 8/15 [53%]), and 100% of the participants desired to participate in future arts-based programming. Following the retreat, a greater percentage of participants believed the arts have a role in the following aspects of clinical practice: education, observation, listening, communication, empathy, compassion, forming connections, cultural sensitivity, tolerance for ambiguity, reflection, mindfulness, stress reduction, preventing burnout, bias prevention, mental wellness, spiritual wellness, and physical wellness (eTable). Qualitative feedback compiled from the participants’ responses to survey questions following the retreat about their thoughts on each activity and overall feedback was used to create a word cloud (eFigure).

Guo eTable
Guo eFig
eFIGURE. Word cloud depicting qualitative feedback compiled from participants’ post-retreat survey responses.

Comment

The importance of arts and humanities integration into medical education previously has been described.5 Our survey results suggest that museum-based programming increases dermatology resident and faculty appreciation for the arts and encourages participation in future arts-based programming. Our results also demonstrate that arts-based programming positively impacts important resident competencies in the practice of medicine including tolerance for ambiguity, bias prevention, and cultural competency, and that the incorporation of arts-based programming can enhance residents’ well-being (physical, mental, and spiritual) as well as their ability to be better clinicians by addressing skills in communication, listening, and observation. The structure of our 3-part museum-based retreat offers practical implementation strategies for integrating the humanities into dermatology residency curricula and easily can be modified to meet the needs of different dermatology residency programs. 

Prior research has demonstrated that museum-based programming decreases resident burnout and depersonalization.1 A partnership between the Museum of Fine Arts Boston and the Harvard Combined Dermatology Residency Program was well received by residents and resulted in improvement of their observational skills.2 The impact of museum-based programming on the clinical practice skills and well-being of Duke dermatology residents and faculty has not been previously assessed.

In this study, our objective was to evaluate the impact of a 3-part museum-based arts retreat on arts appreciation, clinical practice skills, and well-being among dermatology resident and faculty participants. Surveys administered before and after the retreat were used to assess the value that participants attributed to the arts in various areas of clinical practice.

Methods

A 3-part museum-based retreat held on February 7, 2024, was developed with a Nasher Museum of Art (Durham, North Carolina) curator (E.R.). Part 1 was a personal response tour in which 15 residents and 3 faculty members were given individualized prompts and asked to identify an art piece in the museum that encapsulated their response; they then were asked to explain to the group why they chose that particular piece. Participants were given 10 minutes to explore the museum galleries to choose their piece, followed by 15 minutes to share their selected work in groups of 3 to 4.

Part 2 encompassed visual-thinking strategies, a research-based method that uses art to teach visual literacy, thinking, and communication skills.2 Using this method, facilitators follow a specific protocol to guide participants in the exploration of an art piece through sharing observations and interpretations.4 Participants were divided into 2 groups led by trained museum educators (including E.R.) to analyze and ascribe meaning to a chosen art piece. Three questions were asked: What’s going on in this picture? What do you see that makes you say that? What else can we find? 

Part 3 involved back-to-back drawing, in which participants were paired up and tasked with recreating an art piece in the museum based solely on their partner’s verbal description. In each pair, both participants took turns as the describer and the drawer.

After each part of the retreat, 5 to 10 minutes were dedicated to debriefing in small groups about how each activity may connect to the role of a clinician. A total of 15 participants completed pre- and post-retreat surveys to assess the value they attributed to the arts and identify in which aspects of clinical practice they believe the arts play a role.

Results

Seventy-three percent of participants (11/15) found the museum-based retreat “extremely useful” or “very useful.” There was a 20% increase in those who attributed at least moderate value to the arts as a clinician after compared to before the retreat (13/15 [87%] vs 8/15 [53%]), and 100% of the participants desired to participate in future arts-based programming. Following the retreat, a greater percentage of participants believed the arts have a role in the following aspects of clinical practice: education, observation, listening, communication, empathy, compassion, forming connections, cultural sensitivity, tolerance for ambiguity, reflection, mindfulness, stress reduction, preventing burnout, bias prevention, mental wellness, spiritual wellness, and physical wellness (eTable). Qualitative feedback compiled from the participants’ responses to survey questions following the retreat about their thoughts on each activity and overall feedback was used to create a word cloud (eFigure).

Guo eTable
Guo eFig
eFIGURE. Word cloud depicting qualitative feedback compiled from participants’ post-retreat survey responses.

Comment

The importance of arts and humanities integration into medical education previously has been described.5 Our survey results suggest that museum-based programming increases dermatology resident and faculty appreciation for the arts and encourages participation in future arts-based programming. Our results also demonstrate that arts-based programming positively impacts important resident competencies in the practice of medicine including tolerance for ambiguity, bias prevention, and cultural competency, and that the incorporation of arts-based programming can enhance residents’ well-being (physical, mental, and spiritual) as well as their ability to be better clinicians by addressing skills in communication, listening, and observation. The structure of our 3-part museum-based retreat offers practical implementation strategies for integrating the humanities into dermatology residency curricula and easily can be modified to meet the needs of different dermatology residency programs. 

References
  1. Orr AR, Moghbeli N, Swain A, et al. The Fostering Resilience through Art in Medical Education (FRAME) workshop: a partnership with the Philadelphia Museum of Art. Adv Med Educ Pract. 2019;10:361-369. doi:10.2147/AMEP.S194575

  2. Zimmermann C, Huang JT, Buzney EA. Refining the eye: dermatology and visual literacy. J Museum Ed. 2016;41:116-122.

  3. Yenawine P. Visual Thinking Strategies: Using Art to Deepen Learning Across School Disciplines. Harvard Education Press; 2013.

  4. Hailey D, Miller A, Yenawine P. Understanding visual literacy: the visual thinking strategies approach. In: Baylen DM, D’Alba A. Essentials of Teaching and Integrating Visual and Media Literacy: Visualizing Learning. Springer Cham; 2015:49-73. doi:10.1007/978-3-319-05837-5

  5. Howley L, Gaufberg E, King BE. The Fundamental Role of the Arts and Humanities in Medical Education. Association of American Medical Colleges; 2020. Accessed December 18, 2025. https://store.aamc.org/the-fundamental-role-of-the-arts-and-humanities-in-medical-education.html

References
  1. Orr AR, Moghbeli N, Swain A, et al. The Fostering Resilience through Art in Medical Education (FRAME) workshop: a partnership with the Philadelphia Museum of Art. Adv Med Educ Pract. 2019;10:361-369. doi:10.2147/AMEP.S194575

  2. Zimmermann C, Huang JT, Buzney EA. Refining the eye: dermatology and visual literacy. J Museum Ed. 2016;41:116-122.

  3. Yenawine P. Visual Thinking Strategies: Using Art to Deepen Learning Across School Disciplines. Harvard Education Press; 2013.

  4. Hailey D, Miller A, Yenawine P. Understanding visual literacy: the visual thinking strategies approach. In: Baylen DM, D’Alba A. Essentials of Teaching and Integrating Visual and Media Literacy: Visualizing Learning. Springer Cham; 2015:49-73. doi:10.1007/978-3-319-05837-5

  5. Howley L, Gaufberg E, King BE. The Fundamental Role of the Arts and Humanities in Medical Education. Association of American Medical Colleges; 2020. Accessed December 18, 2025. https://store.aamc.org/the-fundamental-role-of-the-arts-and-humanities-in-medical-education.html

Issue
Cutis - 117(1)
Issue
Cutis - 117(1)
Page Number
10,15, E7-E8
Page Number
10,15, E7-E8
Publications
Publications
Topics
Article Type
Display Headline

Impact of a Museum-Based Retreat on the Clinical Skills and Well-Being of Dermatology Residents and Faculty

Display Headline

Impact of a Museum-Based Retreat on the Clinical Skills and Well-Being of Dermatology Residents and Faculty

Sections
Inside the Article

Practice Points

  • Arts-based programming positively impacts resident competencies that are important to the practice of medicine.
  • Incorporating arts-based programming in the dermatology residency curriculum can enhance resident well-being and the ability to be better clinicians.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Dark-Brown Macule on the Periumbilical Skin

Article Type
Changed
Display Headline

Dark-Brown Macule on the Periumbilical Skin

THE DIAGNOSIS: Seborrheic Keratosis

Histopathology revealed epidermal hyperplasia and hyperkeratosis with no notation of atypical melanocytic activity (Figure). There were no Kamino bodies, junctional nesting, or cytologic atypia. Based on these features as well as the clinical and dermoscopic findings, a diagnosis of an inflamed seborrheic keratosis (SK) was made. No further treatment was required following the shave biopsy, and the patient was reassured regarding the benign nature of the lesion.

figure
FIGURE. Histopathology of the periumbilical lesion showed epidermal hyperplasia and hyperkeratosis without melanocytic atypia (H&E, original magnification ×100).

Seborrheic keratoses are benign epidermal growths that can manifest on any area of the skin except the palms and soles. They present clinically as tan, yellow, gray, brown, or black with a smooth, waxy, or verrucous surface. They range from 1 mm to several centimeters in diameter. Although SKs traditionally manifest more frequently in individuals with lighter skin tones, pigmented variants, such as dermatosis papulosa nigra, have been reported to occur more commonly and at younger ages in patients with skin of color.1

Dermoscopy of SK in patients with skin of color can present diagnostic challenges, as these lesions may display atypical pigmented patterns that overlap with melanocytic lesions, including Spitz nevi, particularly when starburstlike or globular structures are present.2 What sets inflamed SKs apart from other SKs is the lack of a heavily keratinized surface on both clinical and dermoscopic evaluation. Common histopathologic diagnostic criteria for Spitz nevi include Kamino bodies, uniform nuclear enlargement, and spindled or epithelioid nevus cells, which were not noted in our patient.3 Therefore, in presentations such as this, histopathology remains the gold standard for diagnosis.

The differential diagnosis in this case included benign nevus, dysplastic nevus, melanoma, and Spitz nevus. Benign nevi typically demonstrate uniform pigmentation and symmetric dermoscopic patterns. Dysplastic nevi may show architectural disorder and cytologic atypia but lack invasive features.3 Melanoma often exhibits asymmetry, atypical network patterns, and irregular pigmentation.4 Spitz nevi characteristically demonstrate large epithelioid or spindle cells with Kamino bodies on histopathology, which were absent in our patient.

References
  1. Greco MJ, Bhutta BS. Seborrheic keratosis. StatPearls [Internet]. StatPearls Publishing; 2025. Updated May 6, 2024. Accessed December 19, 2025. https://www.ncbi.nlm.nih.gov/books/NBK545285/
  2. Emanuel P, Cheng, H. Spitz naevus pathology. Accessed November 25, 2025. https://dermnetnz.org/topics/spitz-naevus-pathology.
  3. Wensley KE, Zito PM. Atypical mole. StatPearls [Internet]. StatPearls Publishing; 2025. Updated July 3, 2023. Accessed December 19, 2025. https://www.ncbi.nlm.nih.gov/books/NBK560606/
  4. Valenzuela FI, Hohnadel M. Dermatoscopic characteristics of melanoma versus benign lesions and nonmelanoma cancers. StatPearls [Internet]. StatPearls Publishing; 2025. Updated August 10, 2024. Accessed December 19, 2025. https://www.ncbi.nlm .nih.gov/books/NBK606113/
Article PDF
Author and Disclosure Information

From OptiSkin Medical, New York, New York.

The authors have no relevant financial disclosures to report.

Correspondence: Orit Markowitz, MD, 1150 Fifth Ave, Ste 1A, New York, NY 10128 (drmarkowitz@optiskinmedical.com).

Cutis. 2026 January;117(1):29, 32. doi:10.12788/cutis.1322

Issue
Cutis - 117(1)
Publications
Topics
Page Number
29, 32
Sections
Author and Disclosure Information

From OptiSkin Medical, New York, New York.

The authors have no relevant financial disclosures to report.

Correspondence: Orit Markowitz, MD, 1150 Fifth Ave, Ste 1A, New York, NY 10128 (drmarkowitz@optiskinmedical.com).

Cutis. 2026 January;117(1):29, 32. doi:10.12788/cutis.1322

Author and Disclosure Information

From OptiSkin Medical, New York, New York.

The authors have no relevant financial disclosures to report.

Correspondence: Orit Markowitz, MD, 1150 Fifth Ave, Ste 1A, New York, NY 10128 (drmarkowitz@optiskinmedical.com).

Cutis. 2026 January;117(1):29, 32. doi:10.12788/cutis.1322

Article PDF
Article PDF

THE DIAGNOSIS: Seborrheic Keratosis

Histopathology revealed epidermal hyperplasia and hyperkeratosis with no notation of atypical melanocytic activity (Figure). There were no Kamino bodies, junctional nesting, or cytologic atypia. Based on these features as well as the clinical and dermoscopic findings, a diagnosis of an inflamed seborrheic keratosis (SK) was made. No further treatment was required following the shave biopsy, and the patient was reassured regarding the benign nature of the lesion.

figure
FIGURE. Histopathology of the periumbilical lesion showed epidermal hyperplasia and hyperkeratosis without melanocytic atypia (H&E, original magnification ×100).

Seborrheic keratoses are benign epidermal growths that can manifest on any area of the skin except the palms and soles. They present clinically as tan, yellow, gray, brown, or black with a smooth, waxy, or verrucous surface. They range from 1 mm to several centimeters in diameter. Although SKs traditionally manifest more frequently in individuals with lighter skin tones, pigmented variants, such as dermatosis papulosa nigra, have been reported to occur more commonly and at younger ages in patients with skin of color.1

Dermoscopy of SK in patients with skin of color can present diagnostic challenges, as these lesions may display atypical pigmented patterns that overlap with melanocytic lesions, including Spitz nevi, particularly when starburstlike or globular structures are present.2 What sets inflamed SKs apart from other SKs is the lack of a heavily keratinized surface on both clinical and dermoscopic evaluation. Common histopathologic diagnostic criteria for Spitz nevi include Kamino bodies, uniform nuclear enlargement, and spindled or epithelioid nevus cells, which were not noted in our patient.3 Therefore, in presentations such as this, histopathology remains the gold standard for diagnosis.

The differential diagnosis in this case included benign nevus, dysplastic nevus, melanoma, and Spitz nevus. Benign nevi typically demonstrate uniform pigmentation and symmetric dermoscopic patterns. Dysplastic nevi may show architectural disorder and cytologic atypia but lack invasive features.3 Melanoma often exhibits asymmetry, atypical network patterns, and irregular pigmentation.4 Spitz nevi characteristically demonstrate large epithelioid or spindle cells with Kamino bodies on histopathology, which were absent in our patient.

THE DIAGNOSIS: Seborrheic Keratosis

Histopathology revealed epidermal hyperplasia and hyperkeratosis with no notation of atypical melanocytic activity (Figure). There were no Kamino bodies, junctional nesting, or cytologic atypia. Based on these features as well as the clinical and dermoscopic findings, a diagnosis of an inflamed seborrheic keratosis (SK) was made. No further treatment was required following the shave biopsy, and the patient was reassured regarding the benign nature of the lesion.

figure
FIGURE. Histopathology of the periumbilical lesion showed epidermal hyperplasia and hyperkeratosis without melanocytic atypia (H&E, original magnification ×100).

Seborrheic keratoses are benign epidermal growths that can manifest on any area of the skin except the palms and soles. They present clinically as tan, yellow, gray, brown, or black with a smooth, waxy, or verrucous surface. They range from 1 mm to several centimeters in diameter. Although SKs traditionally manifest more frequently in individuals with lighter skin tones, pigmented variants, such as dermatosis papulosa nigra, have been reported to occur more commonly and at younger ages in patients with skin of color.1

Dermoscopy of SK in patients with skin of color can present diagnostic challenges, as these lesions may display atypical pigmented patterns that overlap with melanocytic lesions, including Spitz nevi, particularly when starburstlike or globular structures are present.2 What sets inflamed SKs apart from other SKs is the lack of a heavily keratinized surface on both clinical and dermoscopic evaluation. Common histopathologic diagnostic criteria for Spitz nevi include Kamino bodies, uniform nuclear enlargement, and spindled or epithelioid nevus cells, which were not noted in our patient.3 Therefore, in presentations such as this, histopathology remains the gold standard for diagnosis.

The differential diagnosis in this case included benign nevus, dysplastic nevus, melanoma, and Spitz nevus. Benign nevi typically demonstrate uniform pigmentation and symmetric dermoscopic patterns. Dysplastic nevi may show architectural disorder and cytologic atypia but lack invasive features.3 Melanoma often exhibits asymmetry, atypical network patterns, and irregular pigmentation.4 Spitz nevi characteristically demonstrate large epithelioid or spindle cells with Kamino bodies on histopathology, which were absent in our patient.

References
  1. Greco MJ, Bhutta BS. Seborrheic keratosis. StatPearls [Internet]. StatPearls Publishing; 2025. Updated May 6, 2024. Accessed December 19, 2025. https://www.ncbi.nlm.nih.gov/books/NBK545285/
  2. Emanuel P, Cheng, H. Spitz naevus pathology. Accessed November 25, 2025. https://dermnetnz.org/topics/spitz-naevus-pathology.
  3. Wensley KE, Zito PM. Atypical mole. StatPearls [Internet]. StatPearls Publishing; 2025. Updated July 3, 2023. Accessed December 19, 2025. https://www.ncbi.nlm.nih.gov/books/NBK560606/
  4. Valenzuela FI, Hohnadel M. Dermatoscopic characteristics of melanoma versus benign lesions and nonmelanoma cancers. StatPearls [Internet]. StatPearls Publishing; 2025. Updated August 10, 2024. Accessed December 19, 2025. https://www.ncbi.nlm .nih.gov/books/NBK606113/
References
  1. Greco MJ, Bhutta BS. Seborrheic keratosis. StatPearls [Internet]. StatPearls Publishing; 2025. Updated May 6, 2024. Accessed December 19, 2025. https://www.ncbi.nlm.nih.gov/books/NBK545285/
  2. Emanuel P, Cheng, H. Spitz naevus pathology. Accessed November 25, 2025. https://dermnetnz.org/topics/spitz-naevus-pathology.
  3. Wensley KE, Zito PM. Atypical mole. StatPearls [Internet]. StatPearls Publishing; 2025. Updated July 3, 2023. Accessed December 19, 2025. https://www.ncbi.nlm.nih.gov/books/NBK560606/
  4. Valenzuela FI, Hohnadel M. Dermatoscopic characteristics of melanoma versus benign lesions and nonmelanoma cancers. StatPearls [Internet]. StatPearls Publishing; 2025. Updated August 10, 2024. Accessed December 19, 2025. https://www.ncbi.nlm .nih.gov/books/NBK606113/
Issue
Cutis - 117(1)
Issue
Cutis - 117(1)
Page Number
29, 32
Page Number
29, 32
Publications
Publications
Topics
Article Type
Display Headline

Dark-Brown Macule on the Periumbilical Skin

Display Headline

Dark-Brown Macule on the Periumbilical Skin

Sections
Questionnaire Body

A 33-year-old man with moderately to deeply pigmented skin presented to the dermatology department with a dark-brown macule in the periumbilical area of more than 1 year’s duration. The patient was otherwise healthy and reported no personal or family history of atypical nevi, nonmelanoma skin cancer, or melanoma. Dermoscopy of the lesion showed a dark brown macule less than 2 mm in diameter with a starburst like pattern and a blue-hued border. A shave biopsy of the lesion was performed.

O_Donnell-Quiz
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date